

ACC.26

MARCH
28 - 30, 2026
NEW ORLEANS

EXPO
GUIDE

EXPO MAP INSIDE!



AMERICAN
COLLEGE of
CARDIOLOGY®

TRANSFORMING
CARDIOVASCULAR
CARE FOR ALL

Jefferson Health

is building on over 200 years of milestones, firsts and historic medical achievements that improve care and create better outcomes for patients.

Together with Lehigh Valley Health Network, we continue our legacy of excellence in cardiovascular care at the Bruce & Robbi Toll Heart and Vascular Institute.

We've integrated our heart services – including cardiology, cardiac surgery, vascular medicine and vascular surgery. Integration means closer collaboration and increased access to advanced cardiac surgery options like a leading heart transplantation program and innovative interventions.

Our history of firsts

- Founded more than two centuries ago with a faculty of four
- The first American medical college to teach students in the clinic with patients
- In 1953 our surgeons were the first to perform successful open-heart surgery using total cardiopulmonary bypass
- One year later we enrolled our first cardiovascular disease fellow
- Jefferson has trained hundreds of physicians as specialists in the care of patients with cardiovascular disease

At Jefferson Health, we're leading the way forward, building on decades of transformative cardiovascular advancements to reach new heights in prevention, treatment and patient outcomes.



**Jefferson
Health**

ACC.26 EXPO GUIDE

ACC.26 offers a multitude of learning opportunities to help you create a full and diverse learning experience.

When you're not attending sessions, stop by the Expo to visit **250+ exhibiting companies and organizations** to see the latest advances in pharmaceuticals, imaging, devices, health IT and the services you need to provide high-quality care to your patients.

Stop by **Heart Park** (#201), for a chance to unwind in a comfortable park-like environment - grab a friend and enjoy an exciting game of pickleball, update your professional head shot, or enjoy puppy love in the **Relax & Recharge Lounge** while recharging your mind and mobile device. Pick up a uACR test, check your non-fasting lipid levels, Lp(a), hs-CRP, and A1C at the **CVD Lab Screening Booth** (#553). Plus, stop by **ACC Central** (#1337) to discover how ACC is helping you transform cardiovascular care for all and purchase your ACC Apparel.

In addition, don't miss the **Learning Destinations**, which offer non-certified, educationally focused areas to expand your educational experience! In the three **Industry-Expert Theaters, Innovation Stage**, and five **Interactive Learning Labs** you'll have opportunities to learn directly from our industry partners across a wide variety of topics. Plus, don't miss the **Future Hub**, focused on how innovation and technology can be used to improve outcomes and care, and the **Health Equity Hub**, a space aimed at ensuring equitable cardiovascular care for all through education, conversation and collaboration.

ACC.26 Learning Destinations and Prime Time Events are not part of ACC.26, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education credit (CE).

Information current as of March 1, 2026 and subject to change. For the most up to date information, download the ACC.26 app.

LEARNING DESTINATIONS

FUTURE HUB

Expo #148

HEALTH EQUITY HUB

Expo #701

INDUSTRY-EXPERT THEATER 1

Expo #2263

INDUSTRY-EXPERT THEATER 2

Expo #2562

INDUSTRY-EXPERT THEATER 3

Expo #2863

INNOVATION STAGE

Expo #2064

INTERACTIVE LEARNING LABS

BMS and J&J Alliance
Room 221

GE Healthcare

Room 222

Room 225

Pfizer

Room 223

Boston Scientific

Room 227

EXPO HOURS

SATURDAY, MARCH 28

9 a.m. - 5 p.m.

Expo Breaks

9:30 a.m. - Noon

1 - 1:30 p.m.

2:30 - 3:45 p.m.

SUNDAY, MARCH 29

9 a.m. - 5 p.m.

Expo Breaks

9:30 - 10:45 a.m.

11:45 a.m. - 12:15 p.m.

1:15 - 1:45 p.m.

2:45 - 4 p.m.

MONDAY, MARCH 30

9 a.m. - 2 p.m.

Expo Breaks

9:30 - 10:45 a.m.

11:45 a.m. - 12:15 p.m.

1:15 - 1:45 p.m.

ACC.26 EXPO GUIDE - FRIDAY, MARCH 27

PRIME TIME EVENTS

6 - 8 p.m.

4513. Impacting Patient Outcomes in ATTR-CM Through Early Recognition and Treatment

Hilton Riverside, Grand Ballroom D

Join this dynamic session featuring leading specialists who will share insights on recent approaches in ATTR-CM diagnosis and management, including ongoing gaps in care and emerging clinical data for a TTR stabilizer in both variant and wild-type disease. This interactive program will also welcome a patient with ATTR-CM who will share their journey live, highlighting diagnostic challenges and their path to patient advocacy.

Nicole Cyrille-Superville, MD (Moderator)

Atrium Health Sanger Health & Vascular Institute

Kevin Alexander, MD, FACC, FHSA

Stanford University

Keith Ferdinand, MD, FACC, FAHA, FASH, FNLA

Tulane School of Medicine

Art Still

Patient Advocate, Still4Life

Joban Vaishnav, MD

Johns Hopkins Medicine

Sponsored by BridgeBio

6:30 - 8 p.m.

4515. To Lead or Not to Lead, That Is the Question

Westin New Orleans

This session explores LINQ's clinical impact and evolving applications, bridging two decades of innovation with the latest insights on arrhythmias in heart failure. Integrating expert perspectives on real-world clinical judgment, we'll discuss device selection strategies across diverse patient profiles, connecting diagnostics to therapeutic devices. Attendees will gain practical, evidence-based frameworks for therapeutic decision-making, ensuring scientific rigor and actionable relevance for the referral cardiology community. Dinner will be served.

Ijeoma Ekeruo, MD, FACC

Cardiac Electrophysiologist

Arrhythmia Care Center, Houston, Texas

Sponsored by Medtronic

7 - 8:30 p.m.

4514. Cracking the Code: Practical Encounters and Evolving Evidence in HF and CKD Care

Hilton Riverside, Grand Ballroom A,
1st Floor

This live, in-person educational activity equips clinicians with practical skills to improve care for patients with heart failure (HF) and chronic kidney disease (CKD). Participants will learn to recognize early indicators and risk factors for HF progression in patients with or at risk for CKD; apply and optimize guideline directed medical therapy (GDMT) across HF phenotypes (HF with reduced ejection fraction [HFrEF], HF with preserved ejection fraction [HFpEF]) and CKD with effective sequencing strategies; and address common misconceptions that delay appropriate GDMT. Expert faculty will review the role of aldosterone in HF and CKD and examine emerging data on aldosterone synthase inhibition. Through case based sessions and interprofessional discussion, attendees will walk away able to practice shared decision making, manage medication safety, and implement team-based workflow strategies for early diagnosis, risk stratification, and therapy optimization.

Javed Butler, MD, MPH, MBA

Distinguished Professor of Medicine

University of Mississippi; Jackson, Mississippi

Maxwell A. and Gayle H. Clappitt Endowed Chair

President and Chief Research Executive

Baylor Scott and White Research Institute

Senior Vice President, Baylor Scott and White Health; Dallas, Texas

Anuradha Lala-Trindade, MD

Associate Professor

Mount Sinai Fuster Heart Hospital

New York, New York

Robert J. Mentz, MD

Associate Professor of Medicine with Tenure

Chief, Heart Failure Section

Duke University Medical Center

Durham, North Carolina

Co-Editor-in-Chief, Journal of Cardiac Failure

Sponsored by Boehringer Ingelheim

PRIME TIME EVENTS

7 - 7:45 a.m.

4503. Voices of Change: Flyrcado in Action

Courtyard Warehouse Arts District

Join us for a dynamic breakfast panel where early adopters share how Flyrcado can reshape cardiac imaging and care. Hear real-world stories from both imagers and referring cardiologists about its impact on clinical practice and patient outcomes. Gain practical insights, ask questions, and connect with peers driving innovation in coronary artery disease (CAD) diagnosis and management.

Jamie Bourque, MD
UVA

April Mann, MBA, CNMT, NCT, RT(N)

Suman Tandon, MD
St. Francis

Sponsored by GE Healthcare

7 - 8 a.m.

4501. Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice

Hilton Riverside, Grand Ballroom D

Transthyretin cardiac amyloidosis (ATTR-CA), a not-so-rare disorder for the practicing cardiologist, is associated with reduced functional capacity, disability, and a low life expectancy. Insights into ATTR-CA pathophysiology and advances in imaging techniques that allow for non-invasive diagnosis have promoted the development of multiple therapies that slow disease progression and improve quality of life and survival. Three therapies are now approved, with two of these approvals obtained in the past year. However, clinicians must initiate targeted therapies for ATTR-CA early in the disease for the best outcomes.

Unfortunately, diagnostic delays remain prevalent due to failure to recognize patterns of common clinical manifestations. Even when clinicians consider ATTR-CA, diagnostic pitfalls can result in misdiagnosis and a missed opportunity for early treatment. These missed opportunities underscore the need for physician education on appropriate screening and diagnostic strategies. In addition, the growing number of therapeutic options presents a challenge for cardiologists unfamiliar with these agents, especially when guideline recommendations do not yet encompass all available treatments.

Sarah Cuddy, MD
Harvard Medical School
Boston, Massachusetts

Vasvi Singh, MD, FACC, FASNC, FSCCT
Midwest Heart and Vascular Specialists
HCA Midwest Health
Overland Park, Kansas

Sponsored by The Mended Hearts For Alynlyam

7 - 8 a.m.

4502. Mastering the Intersection: Applying Non-Steroidal MRAs in Cardio-Kidney-Metabolic Disease

Hilton Riverside, Grand Ballroom A & B, 1st Floor

Metabolic dysfunction drives substantial morbidity, mortality, and health burden across type 2 diabetes (T2D), chronic kidney disease (CKD), and heart failure (HF), yet screening and treatment remain suboptimal. With rising prevalence and persistent residual risk, clinicians need timely, practical education to improve early recognition and confidently apply evidence-based therapies—especially non-steroidal mineralocorticoid receptor antagonists (nsMRAs)—for these complex, interrelated conditions.

Join expert faculty for a dynamic Test-and-Teach symposium that brings real-world cardiovascular-kidney-metabolic (CKM) cases to life while clarifying when and how to use nsMRAs across heart failure with preserved ejection fraction (HFpEF), CKD in T2D, and emerging type 1 diabetes (T1D) evidence. Strengthen your diagnostic skills, treatment confidence, and shared decision-making approaches to optimize outcomes for high-risk patients.

Vanessa Blumer, MD

Advanced Heart Failure and Transplant Cardiology
Associate Director, Heart Failure Research
Medical Co-Director, Heart Failure Outreach
Inova Schar Heart and Vascular
Falls Church, Virginia

Javed Butler, MD, MPH, MBA

Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi
Maxwell A. and Gayle H. Clampitt Endowed Chair
President and Chief Research Executive
Baylor Scott and White Research Institute
Senior Vice President
Baylor Scott and White Health
Dallas, Texas

Jennifer Green, MD

Professor of Medicine
Division of Endocrinology, Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

Sponsored by Bayer

ACC.26 EXPO GUIDE - SATURDAY, MARCH 28

PRIME TIME EVENTS

5:30 - 7 p.m.

4506. HCM Headlines Game-Changing Advances in Treatment

Hilton Riverside, Grand Ballroom A & B, 1st floor

Hypertrophic cardiomyopathy (HCM) remains underrecognized, often mimicking more common cardiovascular conditions and leading to delays in diagnosis and gaps in care. Join our panel of experts for a news-style symposium to get high-impact updates on the latest advances in identifying HCM and the emerging evidence on cardiac myosin inhibition (CMI) therapy to optimize individualized treatment. Register now and join us to stay ahead of the headline, and elevate your ability to deliver precise, patient-centered HCM care!

Ahmad Masri, MD, MS

Associate Professor of Medicine
Cardiomyopathy Section Head
Director, Hypertrophic Cardiomyopathy Center
Director, Cardiac Amyloidosis Program
Oregon Health & Science University
Portland, Oregon

Amy B. Marzolf, CRNP, MSN

Acute Care Nurse Practitioner
Penn Heart and Vascular Center
Philadelphia, Pennsylvania

Nosheen Reza, MD, MS, FACC, FHSA

Assistant Professor of Medicine
Penn Center for Inherited Cardiovascular Disease
Section of Advanced Heart Failure, Transplantation, and Mechanical Support
University of Pennsylvania
Philadelphia, Pennsylvania

Sponsored by Cytokinetics

6 - 8 p.m.

4504. From Bench to Bedside: RNAi Therapeutics in Cardiovascular Diseases

New Orleans Marriott, Acadia Ballroom

This symposium will highlight how Nobel Prize-winning RNA interference (RNAi) has progressed from foundational science to a clinically validated therapeutic modality in cardiovascular disease. The program will connect RNAi platform innovation to clinical and translational insights. Attendees will gain insights into:

- RNAi platform fundamentals - mechanism of action, delivery technologies, and organ-specific targeting
- RNAi in cardiovascular disease - a focused deep dive into ATTR-CM, including disease biology, rationale for TTR silencing, and emerging evidence from HELIOS-B
- Translational applications beyond rare disease - including RNAi investigation in hypertension
- Future directions in RNAi innovation - next-generation platforms, delivery technologies, and early pipeline programs aiming to shape the future of cardiovascular care

Kirk Brown

VP, Research
Alnylam Pharmaceuticals

Farooq Sheikh, MD, FACC

Medical Director
Advanced Heart Failure Program
MedStar Heart and Vascular Institute
Associate Professor of Medicine
Georgetown University School of Medicine

Sponsored by Alnylam Pharmaceuticals

6:30 - 8:30 p.m.

4505. Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction

Hilton Riverside, Grand Ballroom C, 1st Floor

This program will equip healthcare professionals to elevate ASCVD prevention through interactive, case-based learning focused on today's most challenging lipid-management gaps. Faculty will guide participants in integrating lipoprotein(a) testing into routine cardiovascular risk assessment, recognizing its role as an independent and under-addressed driver of ASCVD. Through brief lectures paired with interactive discussions, attendees will apply current guideline recommendations to develop individualized lipid-lowering strategies, including nonstatin and combination therapies. The session will also address clinical inertia and patient-centered barriers, empowering clinicians to implement guideline-directed care that improves real-world outcomes.

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System

Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert

Associate Professor of Research, Preventive Cardiology PA
Intermountain Advanced Lipid and Cardiovascular Prevention Clinic
Intermountain Health

Erin Michos, MD, MHS, FAHA, FACC, FASE, FASPC

Professor of Medicine
Director of Women's Cardiovascular Health
Associate Director of Preventive Cardiology
Core Faculty, Advanced Lipid Clinic
Division of Cardiology
Johns Hopkins University School of Medicine

Pam R. Taub, MD, FACC, FASPC

Step Family Director's Endowed Chair
Director of Preventive Cardiology
Director of Step Family Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System

Sponsored by Clinical Care Options, LLC dba Decera Clinical Education. Supported by an educational grant from Novartis Pharmaceuticals Corporation.

FUTURE HUB

Expo, #148

9:45 – 10 a.m.

8000. Introduction to Future Hub 2026: AI & Implementation Across Cardiology

This session will introduce the Health Care Innovation Section and Future Hub 2026.

Krishna Pundi, MD, FACC

Cardiac Electrophysiologist, Instructor of Medicine
Palo Alto VA Medical Center
Stanford University

10 – 11 a.m.

8001. Successful Implementation of Clinical AI Tools/Best Practices

The session will feature a panel discussion on the successful implementation of clinical AI tools, highlighting challenges overcome, lessons learned, and key takeaways from implementation science. Panelists will share their experiences championing and incorporating AI tools within their institutions.

Kartik Agusala, MD, FACC (Moderator)
UT Southwestern Medical Center

Jane A. Linderbaum, ARNP, CNP, FACC (Moderator)
Associate Professor of Medicine
Mayo Clinic

Pierre Elias, MD

Assistant Professor in the Division of Cardiology and the Department of Biomedical Informatics
Columbia University Irving Medical Center

Jon Hart

Chief Executive Officer
TAILRD | Heart

Ajay J. Kirtane, MD

Professor of Medicine
Director, Columbia Interventional Cardiovascular Care Chief Academic Officer, Division of Cardiology/Columbia University Irving Medical Center

Fabio V. Lima, MD, MPH, FACC

Structural Heart Specialist, Interventional Cardiology
Florida Cardiac Consultants; Sarasota Memorial Hospital
Clinical Assistant Professor, Florida State University

11 a.m. – Noon

8002. Medicolegal Framework Around Clinical AI Tools (Pitfalls and Pearls)

This 60-minute panel discussion will focus on the legal responsibility associated with medical errors in the context of AI. Who bears accountability – the provider, the health system that funds the product, the vendor, or others? Additionally, should AI be regulated and treated similarly to other medical devices?

Kartik Agusala, MD, FACC (Moderator)
UT Southwestern Medical Center

Anjali B. Thakkar, MBA, MD (Moderator)
Palo Alto Foundation Medical Group

Kenneth Civello, MD, MPH

Director of Electrophysiology
Our Lady of the Lake Hospital

Thomas M. Maddox, MD, MSc, FACC

Director, Clinical Innovation, Department of Medicine
Washington University School of Medicine in St. Louis

2:30 – 3:30 p.m.

8003. It's Already in my Inbox—Now What? Building Digital Clinic Workflows

Wearables are everywhere, and patients expect you to understand how to use their data in making clinical decisions. From sleep quality to Afib burden, this panel of leaders in digital health, implementation science, and health equity will share lessons on remote care models, empowering patients to wield their data, and building value propositions for clinical support.

Krishna Pundi, MD, FACC (Moderator)
Cardiac Electrophysiologist, Instructor of Medicine

Palo Alto VA Medical Center/Stanford University

Emeka Anyanwu, MD, MScBMI

Associate Director, Center for Cardiovascular Informatics
University of Pennsylvania

Maulik Majmudar, MD

Chief Medical Officer
Biofourmis

Lisa Roelle, MMS, PA-C

Pediatric Electrophysiology Physician Associate
Washington University School of Medicine

Jay Shah

Chief Medical Safety Officer
VP Clinical Oversight & Innovation
iRhythm Technologies

Mellanie True Hills, CSP

Chief Executive Officer
American Foundation for Women's Health
StopAfib.org

3:30 – 3:45 p.m.

8004. OpenEvidence in Cardiovascular Medicine: AI to Organize the World's Medical Information

Cardiometabolic care is defined by robust, continually evolving, evidence based pathways, informed by the best medical evidence. This session will highlight the practical use of the OpenEvidence platform to help cardiologists rapidly organize, synthesize, and apply medical evidence at the point of care. The talk will focus on how structured, transparent evidence aggregation can surface high-quality data across trials and guidelines, and support evidence-based decision-making in high-stakes clinical scenarios. By making the underlying evidence more accessible, traceable, and clinically interpretable, OpenEvidence helps ensure that day-to-day cardiovascular care remains aligned with the best available science.

Ankeet Bhatt, MD, MBA, ScM

Kaiser Permanente San Francisco Medical Center

Sponsored by OpenEvidence

4:15 – 5:15 p.m.

8005. Future Hub Innovation Pitch Competition: Technologies Advancing Invasive Procedures

Selected from a competitive pool of global applicants, four finalist companies will take the stage to present their ventures to a distinguished panel of judges. Each finalist will have five minutes to deliver their pitch, followed by a Q&A with the judges.



CardioTwin

 **Massachusetts General Hospital**
Founding Member, Mass General Brigham

 **medipixel**

 **werve
medical**

HEALTH EQUITY HUB

Expo, #701

10 - 11 a.m.

4700. Health Equity Hub Opening Showcase: ACC Health Equity Programs in the Community

Get ready to kick off the Health Equity Hub with an electrifying opening session that showcases outstanding leadership, celebrates remarkable achievements, and sparks inspiration for what's next! Since the integration of health equity into the American College of Cardiology's 2024 - 2028 Strategic Plan, the College has implemented many community-based initiatives and programs. During this session, audience members will learn about the design, implementation, and outcomes of each program and how they align with the strategic goals and priorities of the College. During the session, key leaders in the College's health equity work will be recognized for their contributions.

Paul Douglass, MD, MACC (Moderator)

Melissa Alvarez, MD

Melvin R. Echols, MD, MSCR, FACC

Keith C. Ferdinand, MD, FACC

Leah Kosyakovsky, MD

Thomas M. Maddox, MD, MSc, FACC

Jennifer H. Mieres, MD, FACC

11 a.m. - Noon

4701. Evidence to Action: The Science and Business Case of Health Equity

Despite continued innovation, persistent inequities exist in cardiovascular outcomes, and these inequities undermine quality metrics, outcomes, and value-based care. This session will build the case of why health equity is a clinical and business imperative through discussions of the scientific evidence of cardiovascular outcomes and care delivery and the economic burden of inequities. Attendees will also learn about how to embed equity into clinical pathways and quality improvement and community-aligned care models into a large integrated health system. Speakers will highlight real-world health equity programs driven by community engagement and population health approaches with measurable outcomes on cardiovascular health. The session will also address the role of clinical leaders and professional societies. Participants will be equipped with immediate, actionable steps they can implement when they return to their practice.

Dipti Itchhaporia, MD, MACC

V. Antoine Keller, MD, FACC

Phillip Levy, MD

Tochi Okwueze, DNP, MBA, FNP-BC, CCK, FACC

2:45 - 3:45 p.m.

4702. From Insight to Impact: Addressing Cardiovascular Burden and Equity Through the Global Burden of CVD and JACC Stats

This session brings together two high-impact JACC data initiatives – the Global Burden of Cardiovascular Disease study and JACC Stats – to examine disparities in cardiovascular burden, outcomes, and equity across populations. Faculty will present the latest Global Burden of CVD findings, discuss their clinical and policy implications, and highlight how JACC Stats complements these insights with U.S.-focused data on disease burden, mortality, and quality of care. The session will also include a brief overview of the updated Global Burden of CVD interactive tool, illustrating how data-driven insights can be applied to research, practice, and advocacy.

Taryn Myers, PMP

Gregory Andrew Roth, MD, MPH

Erica S. Spatz, MD, MHS, FACC

Rishi K. Wadhera, MD, MPP, MPHil

INDUSTRY-EXPERT THEATER 1

Expo, #2263

10:30 - 11:30 a.m.

4001. Advancing Cardiovascular Care From Diagnosis to Therapy

Join us for a dynamic, case driven session highlighting real-world use of Abbott Cardiovascular solutions across the heart disease continuum of care. This interactive session will discuss practical insights on multiple Abbott products, including AVEIR™ Leadless Pacemaker, Assert IQ™, CardioMEMS™, Navitor™, MitraClip™, TriClip™, and Perclose™ ProStyle™ Suture-Mediated Closure and Repair System, offering fresh perspectives you can bring directly to your practice.

Khaled I. Khalaf, MD, FACC, FSCAI

Interventional & Structural Cardiologist, Vital Heart & Vein Associate Program Director, HCA Houston Cardiology Fellowship Core Faculty, HCA Houston Internal Medicine Residency Program

Devi G. Nair, MD, FACC, FHRS

Director of the Cardiac Electrophysiology Division
St. Bernard's Heart & Vascular Center
Jonesboro, Arkansas

Matthew Summers, MD, FACC

Structural Heart Program Director
Sentara Health
Norfolk, VA

Sponsored by Abbott

12:30 - 1:30 p.m.

4002. Make It Standard: Lp(a) Integration For CV Risk Impact

A disease state (non-CME), presentation by leading medical experts, including a unique patient perspective from someone diagnosed with elevated Lp(a). This program will focus on the relationship between elevated Lp(a) and premature CAD, as well as the clinical implications of Lp(a) elevation post-ACS.

Christie M. Ballantyne, MD, FACP, FACC

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, FPCNA (hon.)

Fatima Rodriguez, MD, MPH, FACC, FAHA, FASPC

Brian C. Farrington

Family Heart Ambassador, Family Heart Foundation

Sponsored by Novartis Pharmaceuticals

2:30 - 3:30 p.m.

4003. Implementation in Action: Closing the Gap in ASCVD

Sponsored by Amgen

INDUSTRY-EXPERT THEATER 2

Expo, #2562

10:30 - 11:30 a.m.

4009. Breaking Barriers: Tackling Uncontrolled and Resistant Hypertension - The Symplicity™ Blood Pressure Procedure

Unlock new possibilities for your hypertension patients! Join us for an engaging session featuring leading experts as we explore cutting-edge complementary treatment options for managing hypertension.

What to Expect:

- Expert Presentations: Gain insights from top professionals in the field.
- Interactive Discussions: Dive deep into the latest guidelines and clinical evidence.
- Real-World Applications: Learn about patient selection, shared decision-making, and compelling case studies on renal denervation.

Don't miss this opportunity to enhance your practice and improve patient outcomes. Together, we can pave the way for innovative hypertension care!

Supreeti Behuria, MD

Northwell Health
Staten Island, NY

Michael J. Bloch, MD

Renown Health
Reno, NV

Jeremy S. Bock, MD, FACC, FSCAI

Virginia Heart
Leesburg, VA

Yvonne Commodore-Mensah, PhD, MHS, BSN, RN, FAAN, FAHA, FPCNA

Johns Hopkins
Baltimore, MD

Tiffany C. Randolph, MD

Cone Health
Greensboro, NC

Sponsored by Medtronic

12:30 - 1:30 p.m.

4010. A New Option For Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM)

This scientific session will showcase the latest development in the management of patients with oHCM, a newly approved cardiac myosin inhibitor. Expert faculty will guide attendees through a comprehensive review of the mechanism of action, efficacy, and safety profile. The session will illustrate practical considerations in identifying suitable candidates for therapy, initiating and monitoring treatment, and integrating treatment into real-world clinical practice. This program aims to enhance understanding of the latest approach in oHCM care and provide optimal patient support.

Katie Halbmaier, DNP, ARNP, ACGN

Associate Professor of Instruction
University of Iowa College of Nursing
Iowa City, IA

Ahmad Masri, MD, MS

Associate Professor of Medicine
Cardiomyopathy Section Head
Director, Hypertrophic Cardiomyopathy Center
Division of Cardiovascular Medicine, School of Medicine
Oregon Health and Science University
Portland, OR

Sponsored by Cytokinetics

2:30 - 3:30 p.m.

4011. Health Disparities in hATTR

This session explores the health disparities associated with hereditary transthyretin amyloidosis (hATTR), a rare genetic condition characterized by the abnormal deposition of amyloid protein in various organs and tissues. We will delve into the epidemiology of hATTR, highlighting how genetic predispositions, geographic distribution, and socioeconomic factors contribute to disparities in diagnosis and treatment access.

Kevin Alexander, MD, FACC

Dmitry Yaranov, MD

Sponsored by AstraZeneca

INDUSTRY-EXPERT THEATER 3

Expo, #2863

10:30 - 11:30 a.m.

4017. Introduction to AMVUTTRA® (vutrisiran)

Join our distinguished faculty as they review the clinical profile of AMVUTTRA for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Andrew Darlington, DO, FACC

Piedmont Heart Institute

Saurabh Malhotra, MD, MPH, FACC, FASNC

Associate Professor of Medicine and Director of Advanced Cardiac Imaging and Cardiac Stress Testing Laboratory
Cook County Health

Sponsored by Alnylam Pharmaceuticals

12:30 - 1:30 p.m.

4018. Groundbreaking Pivotal Trial and Growing Real-World Experience With CAMZYOS® in Patients With Symptomatic NYHA Class II-III Obstructive HCM

Join this session to review data from pivotal, long-term and real-world studies on the impact of CAMZYOS in adult patients with symptomatic NYHA Class II-III obstructive HCM.

Richard Wright, MD, MACC

Pacific Heart Institute; Cedars-Sinai Medical Center
Santa Monica, CA

Sponsored by Bristol Myers Squibb

2:30 - 3:30 p.m.

4019. Treatment Spotlight For Adult PAH Patients: Clinical Evidence and Insights

- Understand four pathways in PAH
- Summarize phase III trial evidence on efficacy, safety, and impact on key clinical outcomes
- Review a proposed treatment algorithm for PAH management

Sponsored by Merck

INNOVATION STAGE

Expo, #2064

9:45 - 10:15 a.m.

4201. Accelerating Cardiac Amyloidosis Diagnosis With AI: Implementation Insights From Mayo Clinic

This session explores exciting initiatives by Mayo Clinic to develop and deploy AI-assisted ECG and echo for enabling early detection of cardiac amyloidosis and generating structured clinical workflows for treatment. The presentation will delve into considerations for implementation, partnership and scalability, with the goal of encouraging practitioners in their own initiatives.

Patricia A. Pellikka, MD

The Betty Knight Scripps Professor of Cardiovascular Disease Clinical Research
President, Mayo Clinic Officers and Councilors
Consultant, Department of Cardiovascular Medicine
Editor-in-Chief, Journal of the American Society of Echocardiography
Mayo Clinic
Rochester, MN

Sponsored by AstraZeneca

10:45 - 11:15 a.m.

4202. She Says/He Says: HFrEF Patient Management in the Contemporary Era of GDMT: A Friendly Debate

In this sure-to-be lively session, Dr. Hrobowski-Blackman, an advanced heart failure and transplant cardiologist, and Dr. Tomassoni, an electrophysiologist, will debate approaches to managing HFrEF patients, to include recent data on sudden cardiac arrest risk.

Tara Hrobowski-Blackman, MD

HCA Florida Largo Hospital
Largo, FL

Gery Tomassoni, MD, FACC, FHRS

Baptist Health Lexington
Lexington, KY

Sponsored by ZOLL

11:45 a.m. - 12:15 p.m.

4203. Pivotal and Cardiac Structure and Function Outcomes With CAMZYOS® in Patients With Symptomatic NYHA Class II-III Obstructive HCM

Join this session to review data from pivotal and long-term data on the impact of CAMZYOS on cardiac structure and function outcomes in adult patients with symptomatic NYHA Class II-III obstructive.

Mariko Harper, MD, FACC

Medical Director,
Hypertrophic Cardiomyopathy Center
Virginia Mason Franciscan Health System

Sponsored by Bristol Myers Squibb

1 - 1:30 p.m.

4204. A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy

Join us for a dynamic fireside chat that explores how understanding a patient's lived experience can impactfully advance care and address unmet treatment needs in plakophilin 2 arrhythmogenic cardiomyopathy (PKP2 ACM). Moderated by the CEO of the SADS Foundation, this fireside chat will bring together the voices of individuals living with PKP2 ACM and the clinicians who care for them to discuss the importance of integrating genetic testing into a patient's diagnostic journey and to highlight both perspectives on evolving PKP2 ACM therapies.

Genevieve Echols

Family Support, Advocacy, & Research Director
SADS Foundation

Walker Frahm

Chief Executive Officer
SADS Foundation

Daniel Judge, MD, FACC, FHFA

Professor of Medicine/Cardiology
Medical University of South Carolina
Edwin W. and Teresa H. Rogers Endowed Professor
Fellowship Program Director, Cardiology
Director of Cardiovascular Genetics
Section of Advanced Heart Failure & Transplant

Sponsored by Lexeo Therapeutics

2:30 - 3 p.m.

4205. AI-Driven Echocardiography: From Insight to Impact

Join us for a live demonstration of echocardiography AI in action. Practical AI is reshaping echocardiography – improving efficiency, reducing ergonomic strain, standardizing care, and expanding patient access. Learn how AI-assisted view classification paired with automated measurements can revolutionize the traditional echo exam. Join us for a live scanning demonstration and a discussion of the real-world workflow consideration that matter most in daily practice.

Robert Burke, MD, FACC, FASE, FSCA

Ashlee M. Davis, ACS, RDCS, RCCS, BSMI, FASE
Chief Technologies, Duke University

Sponsored by Siemens Healthineers

BMS AND J&J ALLIANCE INTERACTIVE LEARNING LAB

Room 221

Sponsored by Bristol Myers Squibb and Johnson & Johnson Alliance

10:45 - 11:45 a.m.

4320. Exploring the Potential of Factor XI Pathway Inhibition in Thromboembolic Diseases

This scientific program will examine the persisting unmet need in ischemic stroke prevention, review the current therapeutic landscape and its limitations, and introduce the scientific rationale for Factor XI inhibition. The session will focus on the ongoing burden of ischemic stroke, the challenges of balancing efficacy and bleeding risk, and emerging evidence that may support potential for a more favorable benefit-risk profile.

2:45 - 3:45 p.m.

4323. Exploring the Potential of Factor XI Pathway Inhibition in Thromboembolic Diseases

This scientific program will examine the persisting unmet need in ischemic stroke prevention, review the current therapeutic landscape and its limitations, and introduce the scientific rationale for Factor XI inhibition. The session will focus on the ongoing burden of ischemic stroke, the challenges of balancing efficacy and bleeding risk, and emerging evidence that may support potential for a more favorable benefit-risk profile.

Don't forget to download the ACC.26 App! Ask Artie, our AI chatbot, questions and get tailored session, exhibitor, and attendee recommendations to help you easily navigate the meeting.

WITH THE APP YOU CAN:



-  **Browse the program**, search for exhibitors and build your perfect itinerary.
-  **Stream sessions** or connect to the poster theater audio 
-  **Ask the experts** your burning questions or participate in polls
-  Join in the fun with the **Where's Artie Scavenger Hunt** and the **CardioSmart Wellness Challenge** for a chance to win prizes
-  **Connect with fellow attendees** with Attendee Connect and Messaging
-  And after it's all over, seamlessly **claim your credit**

To get started, search **ACC.26** in your app store or scan the QR code from your device (available for Apple® and Android® devices).



GE HEALTHCARE INTERACTIVE LEARNING LAB #1

Room 222

Sponsored by GE Healthcare

10 - 10:30 a.m.

4301. Clinical Considerations For Cardiovascular Imaging in Women: The Critical Role of PET

Cardiovascular disease remains the leading cause of morbidity and mortality in women, yet it is frequently underdiagnosed due to sex-specific differences in disease presentation and pathophysiology. Traditional imaging modalities may be limited in women because of smaller coronary vessel size, higher prevalence of non-obstructive coronary artery disease, microvascular dysfunction, and confounding factors such as breast attenuation and hormonal influences.

Positron Emission Tomography (PET) offers unique advantages in the evaluation of cardiovascular disease in women, including superior spatial resolution, routine attenuation correction, and the ability to quantify absolute myocardial blood flow and coronary flow reserve. These capabilities enable more accurate detection of ischemia, identification of coronary microvascular dysfunction, and improved risk stratification—areas where conventional imaging often falls short. Incorporating PET into clinical decision-making allows for a more personalized and precise assessment of cardiovascular risk in women, ultimately supporting earlier diagnosis, targeted therapy, and improved outcomes.

Rupa M. Sanghani, MD
Rush

11 - 11:30 a.m.

4302. Cardiac PET Clarity: Applying the Latest Recommendations to Patient Selection

Gain confidence in selecting the right patients for cardiac PET by diving into the most up-to-date society guidelines and appropriate-use criteria. This interactive learning lab will review key recommendations from leading organizations, outline clinical scenarios where PET delivers unique value, and provide practical decision-making tools to help you apply evidence-based criteria in real-world practice. Through case examples and discussion, you'll learn how to optimize patient care by aligning the right test with the right patient at the right time.

Marcelo Fernando DiCarli, MD
B&W

Noon - 12:30 p.m.

4303. Uncovering Hidden Disease: Flyrcado Case Review Lab

Step inside the Flyrcado Case Review Lab and explore real-world patient cases that reveal the true power of cardiac PET. See how advanced imaging with Flyrcado™ uncovered disease that other modalities missed, and how these insights changed care decisions and improved outcomes. This interactive learning experience will highlight the clinical value of cardiac PET, demonstrate its impact on referral pathways, and give you practical takeaways for applying these insights in your practice.

Mouaz H. Al-Mallah, MD
Houston Methodist

Mahmoud Al Rifai, MD
Houston Methodist

3 - 3:30 p.m.

4305. Implementing Shared Cardiac PET Services: Operational Considerations

This session explores the practical steps for launching and managing shared cardiac PET services across multiple sites or departments. Learn how to design workflows that optimize efficiency, coordinate between cardiology and nuclear medicine teams, and ensure smooth scheduling and patient throughput. Real-world examples will highlight strategies for overcoming common operational challenges.

Jaime Warren, EdD, MBA, BHS, CNMT, NCT
MedAxiom

3:30 - 4 p.m.

4306. Implementing Shared Cardiac PET Services: Technical Considerations

Dive into the technical aspects of shared cardiac PET implementation, including equipment requirements, tracer logistics, image acquisition protocols, and quality assurance standards. This session will address how to maintain consistency across sites, leverage technology for scalability, and ensure compliance with accreditation guidelines.

Jaime Warren, EdD, MBA, BHS, CNMT, NCT
MedAxiom

4 - 4:30 p.m.

4307. Implementing Shared Cardiac PET Services: Building a Sustainable Business Case

Understand the financial framework for shared cardiac PET services, from cost modeling and budgeting to reimbursement models. This session will provide insights into building a sustainable business case, understanding and addressing payor requirements, and identifying opportunities for efficiencies and cost-sharing.

Nicole Knight, LPN, CPC, CCS-P
MedAxiom

GE HEALTHCARE INTERACTIVE LEARNING LAB #2

Room 225

Sponsored by GE Healthcare

9:30 – 10:30 a.m.

4360. Pioneering Advancements in Echocardiography

- Be introduced to the latest development in echo at GE HealthCare the Vivid Pioneer
- Advancements in 2D and 4D imaging in Adult and Peds, TTE and TEE
- Innovations in color flow and doppler imaging
- Experience how artificial intelligence can help your day to day
- Latest developments in 4D rendering and quantification
- 30-minute intro to machine followed by hands-on the technologies on EchoPac.

Jacob Dewees, RDCS

Clinical Luminary Leader, GE HealthCare, CVUS

11 a.m. – Noon

4363. Intro to Strain Imaging: Bringing AFI into Your Echo Lab

30-minute lecture followed by 30 minutes hands-on

- Introduction to Strain measurement and its importance
- Discover how artificial intelligence has improved Strain Analysis
- Review case studies from real patients
- Understand proper measurement techniques, editing and common pitfalls
- Understanding Myocardial Strain results both regionally and globally

Christos Mihos, DO

Director, Echocardiography & Non-Invasive Cardiovascular Laboratory, Division of Cardiology
Mount Sinai Medical Center, Miami, FL

1 – 2 p.m.

4364. AFI Strain Imaging in Cardio-Oncology

30-minute lecture followed by 30 minutes hands-on

- Learn to interpret changes in GLS values to risk-stratify patients receiving cardiotoxic therapies
- Discover how artificial intelligence creates consistency in Strain Analysis
- Review Strain case studies of patients with Cardiac Toxicity
- Understand proper measurement techniques
- Understanding Myocardial Strain results

Christos Mihos, DO

Director, Echocardiography & Non-Invasive Cardiovascular Laboratory, Division of Cardiology
Mount Sinai Medical Center, Miami, FL

2:30 – 3:30 p.m.

4365. AFI Strain in Hypertrophic Cardiomyopathies

- Understand the role and diagnostic utility of Strain imaging Hypertrophic Cardiomyopathy
- The differences in Strain measurements of HCM and Hypertensive Heart
- Get hands on learning using EchoPac on real cases

Christos Mihos, DO

Director, Echocardiography & Non-Invasive Cardiovascular Laboratory, Division of Cardiology
Mount Sinai Medical Center, Miami, FL

4 – 4:45 p.m.

4366. 4D Valves: Cropping and Multiplanar Reconstruction of 4D TEE

- Learn how to manipulate 4D TEE Echo images
- Review valve orientations needed for Structural Valve Procedures and surrounding anatomical landmarks on 4D TEE
- Discover the methods of Multi-Planar Reconstruction (Flexi-Slice)
- Learn how MPRs Flexi-Slice can help with procedural guidance and measurements
- Practice manipulating 4D images from real cases

PFIZER INTERACTIVE LEARNING LAB

Room 223

Sponsored by Pfizer

2 – 3 p.m.

4380. Getting ATTR-CM Nuclear Scintigraphy Right: Practical Guidance For Clinical Practice

Cardiac nuclear scintigraphy is central to the noninvasive diagnosis of ATTR CM, yet variability in acquisition and interpretation can affect diagnostic confidence. This session provides practical guidance on appropriate clinical suspicion, optimization of SPECT based image acquisition, and accurate interpretation of PYP/HMDP studies. Using illustrative cases, faculty will highlight key principles, common pitfalls, and best practices to support appropriate use of nuclear imaging.

3:15 – 4:15 p.m.

4382. Optimizing ATTR-CM Care: Interpreting Change Over Time

Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive disease in which clinical, imaging, and laboratory findings may evolve at different rates. This session focuses on optimizing longitudinal patient care using a guidance informed approach to interpreting change over time. Through case-based discussion, faculty will explore how to navigate disease progression, emphasizing thoughtful assessment of symptoms, functional status, imaging, and biomarkers within the broader clinical context.

BOSTON SCIENTIFIC INTERACTIVE LEARNING LAB

Room 227

Sponsored by *Boston Scientific*

10 a.m. - Noon

4340. AGENT Virtual Reality Case Experience

Step into the lab and experience a previously recorded live case in virtual reality to learn from operators firsthand. Cases are 30 mins and will begin at 10 a.m., 10:30 a.m., 11 a.m., and 11:30 a.m.

12:30 - 1:30 p.m.

4341. Breaking NEWS in PE: HI-PEITHO Clinical Trial Results - Implications to Patient Care

In this session, a multidisciplinary panel of leaders in pulmonary embolism will examine the results and real-world impact of the recent HI-PEITHO data release. This multi-country, multicenter landmark RCT was designed and conducted in partnership between society, industry, and academia to achieve impactful results through robust study design and large patient population to address to answer the biggest questions in pulmonary embolism care today.

Michael R. Jaff, DO, FACP, FACC (Moderator)

Erik Klok, MD, PhD

Stavros Konstantinides, MD, FESC

Peter Monteleone, MD, FACC, FSCAI

Soophia Naydenov, MD, FCCP

Gregory Piazza, MD, MS

Kenneth Rosenfield, MD, MSC, MHCDS, MSCAI

Andrew Sharp, MBChB, MD, FRCP

Michael Young, MD, FSCAI, RPVI

2:30 - 3:30 p.m.

4342. Calcium IVUS Image Interpretation Laptop Session

Want to use your Boston IVUS like a pro? Join one of our laptop sessions where we'll walk you through the AVVIGO+ interface, share workflow tips, and use case examples to sharpen your IVUS interpretation skills. Seats are limited and will be assigned on a first-come, first-served basis.

4 - 5 p.m.

4343. Title to be Announced

PARTICIPATE IN THE FUN AT


ACC.26

Take part in fun and friendly competitions with your peers and work your way up the leaderboard for a chance to win prizes in the Where's Artie Scavenger Hunt and the CardioSmart Wellness Challenge! Select Challenges in the App to start playing!



Where's Artie Scavenger Hunt

Find Artie in various sessions or locations, scan the QR code or enter the code to collect points. The top 3 winners will receive complimentary registration to ACC.27-WCC in Houston and the next 25 winners will receive a Where's Artie coffee mug!



CardioSmart Wellness Challenge

Track your steps using your Fitbit, Apple Watch, Garmin or step tracker on your mobile device and work your way up the leaderboard to win prizes! Stop by the check-in desk in Lobby A or visit hekahealth.com/acc26 to learn more, sign up and check out the leaderboard. The Wellness Challenge starts on Saturday at noon and ends on Monday at noon.

Supported by:



novo nordisk®



ACC.26 EXPO GUIDE - SUNDAY, MARCH 29

PRIME TIME EVENTS

6:30 - 8 a.m.

4507. New Pathways in Antithrombotic Therapy

Hilton Riverside, Grand Ballroom A & B

Thromboembolic disease is responsible for 1 in every 4 deaths throughout the world. Though currently available anticoagulants can significantly reduce the risk of thromboembolism in patients with atrial fibrillation (AF), venous thromboembolism (VTE), stroke, and other cardiovascular conditions, they are often underutilized in eligible patients or utilized inappropriately primarily due to safety concerns, leading to suboptimal patient outcomes. Emerging evidence suggests that factor XI is a promising new target for inhibition of pathological thrombosis with minimal impairment to physiological hemostasis, paving the way toward a safer anticoagulation strategy. Through immersive patient journeys and expert commentary, this symposium will empower learners to make individualized, evidence-based decisions and be prepared for the integration of novel anticoagulants into clinical practice.

Geoffrey D. Barnes, MD, MSC

Associate Professor, Cardiovascular and Vascular Medicine
Frankel Cardiovascular Center
University of Michigan Medical School
Ann Arbor, Michigan, United States

Carolyn S. P. Lam, MBBS, PhD

Senior Consultant Cardiologist, National Heart Centre
Professor, Duke-National University of Singapore
Singapore, Singapore

Christian T. Ruff, MD, MPH

Associate Professor of Medicine, Harvard Medical School
Director of General Cardiology, Brigham and Women's Hospital
Senior Investigator, TIMI Study Group
Boston, Massachusetts, United States

Sponsored by an educational grant from the Bristol Myers Squibb and Janssen Pharmaceuticals, Inc. Alliance.

7 - 8 a.m.

4508. Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM?

Hilton Riverside, Grand Ballroom D

Obstructive hypertrophic cardiomyopathy (oHCM) affects up to 1 in 200 individuals and is associated with increased morbidity and mortality compared with the general population. Historically, treatment has focused on pharmacologic and surgical interventions that alleviate symptoms. The introduction of cardiac myosin inhibitors (CMI) represented a major advance by targeting the pathophysiology of oHCM. Long-term and real-world evidence are accumulating, confirming that CMIs improve symptoms, exercise capacity, and functional status in oHCM while also reducing the need for septal reduction therapy (SRT). Importantly, these benefits have been observed across diverse patient populations, including groups historically underdiagnosed or underrepresented in HCM research (eg, Black individuals, women), supporting the broad applicability of disease-modifying therapy in oHCM management.

The availability of CMIs has introduced new complexities in clinical decision-making. Cardiologists and other oHCM care team members must now navigate evolving guideline recommendations, interpret rapidly emerging clinical and real-world data, and integrate expanded indications and updated risk evaluation and mitigation strategies (REMS) into care. They must also differentiate between therapies that target the underlying disease mechanism from those that only provide symptomatic relief, ensuring treatment selection is personalized, evidence-based, and reflective of patient preferences. Effective team collaboration – among general and subspecialty cardiologists, NPs, PAs, and others – is essential to the safe implementation of CMIs to improve patient outcomes and ensure equitable access to care.

Milind Desai, MD, MBA

Haslam Family Endowed Chair in CV Medicine
Professor of Medicine, Vice Chair and Director, HCM Center
Heart Vascular Thoracic Institute
Cleveland Clinic, Cleveland, Ohio

Anjali Tiku Owens, MD

Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Sponsored by The Mended Hearts

7 - 8 a.m.

4509. Revolutionizing Recurrent AMI Care: Addressing Unmet Needs With Early Intervention Strategies

Hilton Riverside, Grand Salon B, 1st Floor

Every 40 seconds, someone in the United States suffers from acute myocardial infarction (AMI), requiring emergency care. The delay from symptom onset to initiation of therapy to reduce the total ischemic time after AMI has not improved in decades. Prolonged ischemic time is strongly associated with poor prognosis after AMI, due to increased myocardial damage and higher risk for death and heart failure. This prolonged time frame underscores the urgent need for strategies that can reduce ischemic time and improve patient outcomes by addressing barriers to timely intervention. In this fast-paced symposium, experts will discuss limitations in current care pathways for recurrent AMI, the rationale for pre-hospital antiplatelet therapies, and the evolving clinical landscape of early interventions.

Deepak L. Bhatt, MD, MPH, MBA

Director of Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, New York, United States

Jennifer A. Rymer, MD, MBA

Associate Professor of Medicine
Duke Clinical Research Institute
Program Director, Interventional Cardiology Fellowship
Duke University, Durham, North Carolina, United States

Professor Philippe G. Steg, MD

Hôpital Bichat, Assistance Publique - Hôpitaux de Paris
Université Paris-Cité, UMR 1148/LVTS
French Alliance for Cardiovascular Trials
Paris, France

Sponsored by Viatrix

ACC.26 EXPO GUIDE - SUNDAY, MARCH 29

PRIME TIME EVENTS (CONT'D)

6:30 - 8 p.m.

4511. Emerging Data and Evolving Guidelines, A Patient-Centered Approach to Evidence-Based Treatment For Aortic Stenosis

New Orleans Marriott Warehouse Arts District, Gravier Ballroom, First Floor

This symposium features a roundtable panel discussion among front-line researchers regarding the latest clinical trials and registry data in the management of aortic stenosis (AS). The expert faculty will discuss two patient case scenarios that illustrate how patient pathways are changing to achieve optimal outcomes in this challenging patient population.

Sreekanth Vemulapalli, MD (Moderator)

Associate Professor of Medicine with Tenure
Director of Cardiovascular Imaging, DUHS
Duke Clinical Research Institute
Duke Margolis Institute for Health Policy
Durham, NC

Kashish Goel, MD, FSCAI, FACC

Director, Transcatheter Valve Interventions
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

Tsuyoshi Kaneko, MD

Evarts A. Graham Professor of Surgery
Division Director of Cardiothoracic Surgery
Washington University School of Medicine
Co-Director, Heart and Vascular Center
Barnes Jewish Hospital
St. Louis, MO

Brian R. Lindman, MD, MSc

Medical Director, Structural Heart and Valve Center
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

Sponsored by Edwards Lifesciences

6:30 - 8:30 p.m.

4510. The Precision Imperative: Integrating AI-Plaque Analysis to Personalize Cardiovascular Risk and Management

Generations Hall, 310 Andrew Higgins Blvd

After participating in this program, attendees will be able to:

- Recognize the growing clinical imperative to evolve cardiovascular risk assessment, as new tools, reimbursement pathways, and scientific evidence converge
- Describe how Heartflow Plaque Analysis informs risk assessment and management strategies for patients with coronary artery disease
- Identify patient populations best suited for Heartflow Plaque Analysis, including those who may benefit from earlier personalized proactive intervention

Nihar Desai, MD (Moderator)

Yale School of Medicine
New Haven, CT

Ron Blankstein, MD

Brigham and Women's Hospital
Boston, MA

Sarah Rinehart, MD

Charleston Area Medical Center

Sponsored by Heartflow

6:30 - 8:30 p.m.

4512. Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidenced-Based Therapies to Optimize Patient Outcomes

Hilton Riverside, Grand Ballroom C, 1st Floor

Cardiology healthcare professionals (HCPs) are crucial in the proper use of evidence-based therapies for patients with cardio-renal-metabolic (CRM) diseases. Clinical inertia continues to limit optimal care delivery for patients with CRM diseases. This program addresses hesitancy among cardiology HCPs and patients to initiate or continue guideline-directed medical therapy.

Ty J. Gluckman, MD, MHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science
Providence Heart Institute
Providence Health System
Portland, OR

Stephen J. Greene, MD

Associate Professor of Medicine, Division of Cardiology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC

Sponsored by Clinical Care Options, LLC dba Decera Clinical Education. Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

FUTURE HUB

Expo, #148

9:30 - 10:30 a.m.

8006. Emerging Sensors and Technologies in CV Medicine

This interactive session will feature three leaders in cardiovascular technology showcasing their latest sensor technologies. Following the demonstrations, members of the planning committee will lead a discussion on practical applications, emerging opportunities, and future directions for these innovations.

Mark Lampert, MD, MBA (Moderator)

Vice Chief, Division of Cardiology
Endeavor Health

Anwar Chahal, MD, PhD, FACC (Moderator)

WellSpan Health

Simona Bor, MD

Medical Affairs and Clinical Affairs Associate
Masimo

Arik Ben Ishay

CEO & Co-Founder
Biobeat

John Martin, MD, MBA

Chief Medical Officer
Cardiosense

10:30 - 10:45 a.m.

8007. Trends in Prescribing of Hormone Replacement Therapy and Cardiovascular Events Among Peri and Post-Menopausal Women Using US Real World Data: 2017 - 2025

This session will highlight the current trends in HRT prescribing among peri-menopausal and post-menopausal and rates of cardiovascular events using a large, US-based, EHR linked to claims database from 2017 - 2025. The speakers will highlight the role that real-world evidence can play in the context of a broader healthcare discussion.

Janna Manjelievskaia, PhD, MPH

Director, Health Economics & Outcomes Research, Real-World Evidence
Veradigm

Jordan Overcash, MSN

Director, Solutions Management, Clinical Insights and Unstructured Data
Veradigm

Sponsored by Veradigm

Noon - 12:15 p.m.

8008. The RNAi Story: From Nobel Discovery to Next-Generation Therapeutics

Explore the scientific evolution of RNA interference (RNAi) from foundational discovery to approved medicines and investigational programs. This brief presentation will place the spotlight on how

human genetics, targeted tissue delivery, and innovative platform designs are shaping the future for RNAi therapeutics, with a forward-focus on aiming to expand their impact across a broader range of diseases.

Kirk Brown, PhD

Vice President of Research
Alnylam

Sponsored by Alnylam

1:15 - 1:30 p.m.

8009. Identifying Guideline Gaps Through Real-World Clinician Queries

The aggregate patterns of real-world clinician queries from point-of-care decision support tools represent a powerful and largely untapped signal of clinical uncertainty and information need. This session presents initial findings from an analysis of more than one million cardiologist queries submitted through OpenEvidence, an AI-powered clinical decision support tool used by over 40% of U.S. physicians, to identify gaps in clinical practice guideline coverage with the aim of supporting future research and guideline development.

Mondira Ray, MD, MBI

Director of Clinical Informatics
OpenEvidence

Sponsored by OpenEvidence

1:30 - 1:45 p.m.

8010. Beyond Prescribing Trends: AI Evaluation of Cardiovascular Symptoms and Clinical Rationale For Hormone Replacement Therapy From Physician Notes

This session will focus on analysis of physician notes at the point of care among eligible women who have vs. have not been prescribed HRT during peri- and post-menopausal years. The speakers will share insights from EHR healthcare provider notes with targeted natural language processing queries and AI-assisted large language models.

Janna Manjelievskaia, PhD, MPH

Director, Health Economics & Outcomes Research, Real-World Evidence
Veradigm

Jordan Overcash, MSN

Director, Solutions Management, Clinical Insights and Unstructured Data
Veradigm

Sponsored by Veradigm

2:45 - 3:05 p.m.

8011. International Digital Health Award Presentation and Pitch

ACC's International Digital Health Work Group is pleased to announce the winner of the first ACC Global Digital Health Award: Medical AI. Based in Seoul, South Korea, Medical AI specializes in artificial intelligence-enabled electrocardiogram solutions for cardiovascular disease detection and monitoring. Join ACC's Chief Innovation Officer, Dr. Ami Bhatt, on the Future Hub Stage for the award presentation.

ACC.26 EXPO GUIDE - SUNDAY, MARCH 29

FUTURE HUB (CONT'D)

3:05 - 4:15 p.m.

8012. Future Hub Innovation Pitch Competition: Noninvasive Technologies

Selected from a competitive pool of global applicants, four finalist companies will take the stage to present their ventures to a distinguished panel of judges. Each finalist will have five minutes to deliver their pitch, followed by a Q&A with the judges.

ACORAI

biozen

**LIFEWAVE
BIOMEDICAL**

**ScriptChain
HEALTH**

HEALTH EQUITY HUB

Expo, #701

9:45 - 10:45 a.m.

4703. The Health Equity Toolkit: Data and Resources to Improve Patient Outcomes

The session will feature three presentations. The first, Mapping the Burden: Using Equity Data to Identify Care Gaps, will feature an interactive demonstration of the ACC Health Equity Heat Map to help attendees "map the burden" of cardiovascular disease and social vulnerability. The second presentation, Reducing Access Gaps Using Implementation Science: Turning Data Into Action, will detail how cardiovascular programs can use data to implement changes, such as strengthening community partnerships and foundation organizations, improving access to diagnostics, coordinating follow up pathways, offering transportation support, and enhancing outreach in areas with persistent gaps. The final presentation, Digital and Community Integration: Leveraging Technology and Community Partnerships to Expand Access, will explore how technology and community partnerships can work together to broaden access to cardiovascular care in high burden areas.

Christina Cantey, DNP, FNP-C, AACC, CCK (Moderator)

Robert O. Roswell, MD, FACC

Misty Theriot, BSN, RN, CPHQ, FACC

3 - 4 p.m.

4704. Championing Communities of Health: A Cross-Industry Panel Discussion on Health Equity Programs

ACC's Strategic Plan prioritizes health equity as a crucial part of the College's future. Without addressing inequities in all aspects of care, it will be impossible to build a future where cardiovascular disease is no longer the #1 killer worldwide. Tackling these challenges requires cross-sector collaboration and commitment. This panel discussion will focus specifically on the College's Health Equity strategy and priorities, the role both the ACC and its partners play in improving patient outcomes and insights from collaborators in the life sciences industry.

Dipti Itchhaporia, MD, MACC (Moderator)

Alice Koehler
Omron Healthcare

Patricia Parada, BS, MEng
Bristol Myers Squibb

American College of Cardiology Representative

Boston Scientific Representative

Johnson & Johnson Representative

INDUSTRY-EXPERT THEATER 1

Expo, #2263

9:30 - 10:30 a.m.

4004. From Suspicion to Strategy: Contemporary ATTR-CM Management in Clinical Practice

This session reviews the essential role of the cardiologist in identifying, diagnosing, and managing transthyretin cardiac amyloidosis (ATTR-CM). Through a patient case study and expert perspectives, the program will review contemporary clinical approaches. Data on an oral therapeutic option, including long-term extension and real-world evidence will be presented. The session will also summarize recently published consensus recommendations for monitoring disease progression.

Sponsored by Pfizer

11:45 a.m. - 12:45 p.m.

4005. Identification and Stratification of Patients at High CV Risk Without a Prior MI or Stroke: Insights From Real-World Evidence and the VESALIUS-CV Trial

Join cardiovascular experts as they explore how to reduce the risk of MACE in patients at high CV risk without a previous MI or stroke. Featuring data from the VESALIUS-CV outcomes trial alongside real-world evidence, this session highlights the urgent need for risk identification and treatment

Matthew Budoff, MD, FACC, FAHA

Sponsored by Amgen

2:45 - 3:45 p.m.

4006. CHAMPION Insights: Advancing Stroke Protection in AF Management

- CHAMPION AF Essentials: The Largest LAAC Trial to Date
- CHAMPION AF and Beyond: Clinical Evidence For Stroke Protection in AF Management
- Practice Ready Evidence: What CHAMPION AF Adds to Clinical Decision Making Today

Megan Coylewright, MD

C. Michael Gibson, MD

Christopher Granger, MD

Saibal Kar, MD

Sponsored by Boston Scientific

INDUSTRY-EXPERT THEATER 2

Expo, #2562

9:30 - 10:30 a.m.

4012. Act When It Matters Most: When to Consider LEQVIO® (inclisiran)

Hear expert insights on the clinical data for LEQVIO® (inclisiran). Don't miss an engaging session that will delve into the latest clinical data, help you identify the appropriate patient profiles, and provide actionable strategies for integrating LEQVIO effectively into your daily practice.

Michael Farbaniec, MD

Director of Cardiovascular Disease Prevention
Penn State Health

Sponsored by Novartis Pharmaceuticals

11:45 a.m. - 12:45 p.m.

4013. Unlocking CV Inflammation in Clinical Practice

This symposium will reinforce understanding of cardiovascular (CV) inflammation pathophysiology, including interleukin-6 (IL-6) signaling and biomarkers such as high-sensitivity C-reactive protein (hsCRP), highlight the unmet needs in diverse cardiovascular disease (CVD) populations and explore inflammation-focused clinical frameworks that can be used to guide CV risk assessment and management strategies.

Antonio Abbate, MD, PhD

Giovanna Liuzzo, MD, PhD, MSc

Guiomar Mendieta-Badimon, MD, PhD, MSc

Paul Ridker, MD, MPH

Sponsored by Novo Nordisk

2:45 - 3:45 p.m.

4014. Elevated Lp(a): Implications For Patient Risk Assessment

Sanjay Kaul, MD

Payal Kohli, MD, FACC

Sponsored by Amgen

INDUSTRY-EXPERT THEATER 3

Expo, #2863

9:30 - 10:30 a.m.

4020. TRYNGOLZA: Proven Results and Real Patient Experiences

Please join Dr. Dharmesh Patel at ACC.26 for a presentation on TRYNGOLZA®, the first FDA-approved therapy for adults with familial chylomicronemia syndrome (FCS) as an adjunct to diet.

Sponsored by Ionis Pharmaceuticals, Inc.

11:45 a.m. - 12:45 p.m.

4021. Evidence-Based Strategies For the Treatment of Recurrent Pericarditis, Recurrent Pericarditis Panel Case Study and Q&A

Recurrent pericarditis (RP) affects ~40,000 people in the U.S. annually. Though rarely life-threatening, flares may cause sharp chest pain, limit activity, and impact mental health. The recent ACC Concise Clinical Guidance publication reflects increased efforts from the cardiology community to improve diagnosis and management of pericardial disease. Join us for a Kiniksa-sponsored promotional product event highlighting evidence-based RP management strategies.

Paul Cremer, MD, FACC

Associate Professor for Medicine (Cardiology) and Radiology
Northwestern University

Dor Lotan, MD

Assistant Professor of Medicine, Division of Cardiology
Center for Advanced Cardiac Care
Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
Columbia University Irving Medical Center-New York Presbyterian Hospital

Syed Wasqas Haider, MD, MPH, FACC

Director, Pericardial Disease Program, Attending Cardiologist
MedStar Heart & Vascular Institute, Washington, DC

Sponsored by Kiniksa Pharmaceuticals

2:45 - 3:45 p.m.

4022. To Be Announced

Sponsored by Eli Lilly & Company

ACC.26 EXPO GUIDE - SUNDAY, MARCH 29

INNOVATION STAGE

Expo, #2064

9:30 - 10 a.m.

4206. The Potential to Reduce HF Readmissions to Single Digits

In this session Chelsea Christensen will discuss how the use of ZOLL's Heart Failure Management System (HFMS) has assisted in reducing 30-day HF readmission rates to single digits.

Chelsea E. Christensen, PA-C

Sentara Virginia Beach General Hospital

Sponsored by ZOLL

11:45 a.m. - 12:15 p.m.

4207. The Future of TAVR & Evolut in Low-Risk Patients

Evolut demonstrates a sustained commitment to clinical innovation by addressing the increasingly complex and evolving requirements of valve selection for patients undergoing TAVR. Explore clinical insights on the use of Evolut TAVR in low-risk patients and examine how AI-driven pre-procedural planning can enhance procedural decision-making.

Sponsored by Medtronic

1:15 - 1:45 p.m.

4208. On ALERT: Using AI-Powered EHR Alerts to Fast Track Evidence Based Care For VHD

Overview of the ALERT trial to evaluate how automated notifications support the identification and evaluation of patients with severe aortic stenosis and mitral regurgitation. The trial aims to address the significant gaps in the recognition and management of severe AS and MR which if left untreated leads to increased morbidity and mortality.

Wayne Batchelor, MD, MHS, MBA

President, Medicine Service Line
Inova Health System

Brian R. Lindman, MD, MSc, FACC

Medical Director, Structural Heart and Valve Center
Associate Professor of Medicine
Vanderbilt University Medical Center

Sponsored by Medtronic

3 - 3:30 p.m.

4209. Decoding a Silent Threat: Uncovering Aldosterone's Impact on Hypertension and Cardiovascular Morbidity

Nearly half of U.S. adults with hypertension (HTN) have uncontrolled blood pressure, despite taking multiple antihypertensive medications. This persistent challenge greatly increases their risk of cardiovascular and kidney complications, as well as mortality. We'll explore the often-overlooked role of aldosterone as a key pathophysiological driver of HTN, which raises the question – could novel treatments targeting aldosterone production be warranted for patients with HTN who remain uncontrolled?

Ankheet Bhatt, MD, MBA, ScM

Sponsored by AstraZeneca

BMS AND J&J ALLIANCE INTERACTIVE LEARNING LAB

Room 221

Sponsored by Bristol Myers Squibb and Johnson & Johnson Alliance

9:45 - 10:45 a.m.

4321. Exploring the Potential of Factor XI Pathway Inhibition in Thromboembolic Diseases

This scientific program will examine the persisting unmet need in ischemic stroke prevention, review the current therapeutic landscape and its limitations, and introduce the scientific rationale for Factor XI inhibition. The session will focus on the ongoing burden of ischemic stroke, the challenges of balancing efficacy and bleeding risk, and emerging evidence that may support potential for a more favorable benefit-risk profile.

3 - 4 p.m.

4324. Exploring the Potential of Factor XI Pathway Inhibition in Thromboembolic Diseases

This scientific program will examine the persisting unmet need in ischemic stroke prevention, review the current therapeutic landscape and its limitations, and introduce the scientific rationale for Factor XI inhibition. The session will focus on the ongoing burden of ischemic stroke, the challenges of balancing efficacy and bleeding risk, and emerging evidence that may support potential for a more favorable benefit-risk profile.

GE HEALTHCARE INTERACTIVE LEARNING
LAB #1

Room 222

Sponsored by GE Healthcare

9:30 - 10 a.m.

4308. Implementing Shared Cardiac PET Services: Operational Considerations

This session explores the practical steps for launching and managing shared cardiac PET services across multiple sites or departments. Learn how to design workflows that optimize efficiency, coordinate between cardiology and nuclear medicine teams, and ensure smooth scheduling and patient throughput. Real-world examples will highlight strategies for overcoming common operational challenges.

Jaime Warren, EdD, MBA, BHS, CNMT, NCT
MedAxiom

10 - 10:30 a.m.

4309. Implementing Shared Cardiac PET Services: Technical Considerations

Dive into the technical aspects of shared cardiac PET implementation, including equipment requirements, tracer logistics, image acquisition protocols, and quality assurance standards. This session will address how to maintain consistency across sites, leverage technology for scalability, and ensure compliance with accreditation guidelines.

Jaime Warren, EdD, MBA, BHS, CNMT, NCT
MedAxiom

10:30 - 11 a.m.

4310. Implementing Shared Cardiac PET Services: Building a Sustainable Business Case

Understand the financial framework for shared cardiac PET services, from cost modeling and budgeting to reimbursement models. This session will provide insights into building a sustainable business case, understanding and addressing payor requirements, and identifying opportunities for efficiencies and cost-sharing.

Nicole Knight, LPN, CPC, CCS-P
MedAxiom

11:30 a.m. - Noon

4311. Uncovering Hidden Disease: Flyrcado Case Review Lab

Step inside the Flyrcado Case Review Lab and explore real-world patient cases that reveal the true power of cardiac PET. See how advanced imaging with Flyrcado™ uncovered disease that other modalities missed, and how these insights changed care decisions and improved outcomes. This interactive learning experience will highlight the clinical value of cardiac PET, demonstrate its impact on referral pathways, and give you practical takeaways for applying these insights in your practice.

Mouaz H. Al-Mallah, MD
Houston Methodist

Mahmoud Al Rifai, MD
Houston Methodist

12:30 - 1 p.m.

4312. Clinical Considerations For Cardiovascular Imaging in Women: The Critical Role of PET

Cardiovascular disease remains the leading cause of morbidity and mortality in women, yet it is frequently underdiagnosed due to sex-specific differences in disease presentation and pathophysiology. Traditional imaging modalities may be limited in women because of smaller coronary vessel size, higher prevalence of non-obstructive coronary artery disease, microvascular dysfunction, and confounding factors such as breast attenuation and hormonal influences.

Positron Emission Tomography (PET) offers unique advantages in the evaluation of cardiovascular disease in women, including superior spatial resolution, routine attenuation correction, and the ability to quantify absolute myocardial blood flow and coronary flow reserve. These capabilities enable more accurate detection of ischemia, identification of coronary microvascular dysfunction, and improved risk stratification—areas where conventional imaging often falls short. Incorporating PET into clinical decision-making allows for a more personalized and precise assessment of cardiovascular risk in women, ultimately supporting earlier diagnosis, targeted therapy, and improved outcomes.

Rupa M. Sanghani, MD
Rush

1:30 - 2 p.m.

4313. Uncovering Hidden Disease: Flyrcado Case Review Lab

Step inside the Flyrcado Case Review Lab and explore real-world patient cases that reveal the true power of cardiac PET. See how advanced imaging with Flyrcado™ uncovered disease that other modalities missed, and how these insights changed care decisions and improved outcomes. This interactive learning experience will highlight the clinical value of cardiac PET, demonstrate its impact on referral pathways, and give you practical takeaways for applying these insights in your practice.

Jamie Bourque, MD
UVA

ACC.26 EXPO GUIDE - SUNDAY, MARCH 29

GE HEALTHCARE INTERACTIVE LEARNING LAB #1 (CONT'D)

2:30 - 3 p.m.

4314. Cardiac PET Clarity: Applying the Latest Recommendations to Patient Selection

Gain confidence in selecting the right patients for cardiac PET by diving into the most up-to-date society guidelines and appropriate-use criteria. This interactive learning lab will review key recommendations from leading organizations, outline clinical scenarios where PET delivers unique value, and provide practical decision-making tools to help you apply evidence-based criteria in real-world practice. Through case examples and discussion, you'll learn how to optimize patient care by aligning the right test with the right patient at the right time.

Marcelo Fernando DiCarli, MD
B&W

3:30 - 4 p.m.

4315. AI in ECG: Clinical Impact and Workflow

Abhishek J. Deshmukh, MBBS
Mayo Clinic

4:30 - 5 p.m.

4316. Trustworthy AI-ECG: Overcoming Limitations of the Black Box

Current state of AI-ECG, limitations and challenges for translation to clinical practice, and a vision for transparent and trustworthy AI-ECG.

Manolis Kargiantoulakis, PhD
GE HealthCare

GE HEALTHCARE INTERACTIVE LEARNING LAB #2

Room 225

Sponsored by GE Healthcare

9:30 - 10:30 a.m.

4361. Intro to Strain Imaging: Bringing AFI Into Your Echo Lab

30-minute lecture followed by 30 minutes hands-on.

- Introduction to Strain measurement and its importance
- Discover how artificial intelligence has improved Strain Analysis
- Review case studies from real patients
- Understand proper measurement techniques, editing and common pitfalls.
- Understanding Myocardial Strain results both regionally and globally

Christos Mihos, DO

Director, Echocardiography & Non-Invasive Cardiovascular Laboratory, Division of Cardiology
Mount Sinai Medical Center, Miami, FL

11 a.m. - Noon

4367. AFI Strain in Amyloid and Cardiomyopathies

- Understand the role and diagnostic utility of Strain in imaging cardiomyopathies
- Impact of amyloid on heart muscle and AFI results.
- Strain patterns in various cardiomyopathies and how to differentiate between constrictive and restrictive cardiomyopathies
- Review case studies of different cardiomyopathies on Echo Pac

Christos Mihos, DO

Director, Echocardiography & Non-Invasive Cardiovascular Laboratory, Division of Cardiology
Mount Sinai Medical Center, Miami, FL

1 - 2 p.m.

4368. Artificial Intelligence in Echo: Using AI and Vivid Technologies to Improve Echo Lab Workflow

- Understand the types of Artificially Intelligent tools that are available in Echo
 - View Recognition
 - Measurements - Cardiac Auto Doppler, Easy AFI, Auto EF
 - Image Acquisition Guidance with Caption
 - Offline analysis and reporting with Echo Pilot on View Point
- Discover other technologies that can help make your Echo Lab more efficient
- Review images on EchoPAC and how to apply AI

Jacob Dewees, RDCS

Clinical Luminary Leader
GE HealthCare , CVUS

2:30 - 3:30 p.m.

4369. Myocardial Work: A New Way of Looking at Heart Function

- Be introduced to the concepts of myocardial work
- Understand how to achieve the measurement of Myocardial Work utilizing Strain AFI on echocardiography
- Discover how Myocardial Work can be utilized in different disease states and the corresponding results
- Get hands-on learning using EchoPac on real cases

Salima Qamruddin, MD

Director, Echo Quality and Research
Director, Women's Cardiovascular Clinic
Ochsner Heart and Vascular Institute
New Orleans LA

4 - 4:45 p.m.

4370. Optimizing 4D Images and Quantification of LV and LA Volumes

- Learn how to optimize 4D volumes
- Discover how to quantify 4D volumes of the left ventricle and left atrium using one tool 4D Auto LVQ
- Learn how to navigate a 4D Volume
- Get hands-on learning using 4D images on EchoPac laptops

PFIZER INTERACTIVE LEARNING LAB

Room 223

Sponsored by Pfizer

10:45 - 11:45 a.m.

4381. Optimizing ATTR-CM Care: Interpreting Change Over Time

Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive disease in which clinical, imaging, and laboratory findings may evolve at different rates. This session focuses on optimizing longitudinal patient care using a guidance informed approach to interpreting change over time. Through case-based discussion, faculty will explore how to navigate disease progression, emphasizing thoughtful assessment of symptoms, functional status, imaging, and biomarkers within the broader clinical context.

BOSTON SCIENTIFIC INTERACTIVE LEARNING LAB

Room 227

Sponsored by Boston Scientific

9:30 - 11 a.m.

4344. ROTAPRO Virtual Reality Case Experience

Step into the lab and experience a previously recorded live case in virtual reality to learn from operators firsthand. Cases are 30 mins and will begin at 9:30 a.m., 10 a.m., and 10: 30 a.m.

11:45 a.m. - 1 p.m.

4345. Renal Denervation in Hypertension Care: Evidence, Innovation, and What's Next

This symposium will examine hypertension as a persistent global health challenge and the ongoing need for novel treatment approaches. The session will review the current renal denervation evidence base, highlighting how clinical trial data have shaped the therapy's evolution. Attendees will learn about emerging ultrasound-based renal denervation techniques, including early experience with TIVUS, and explore how upcoming evidence from the THRIVE trial may further define the role of RDN in clinical practice. The program will provide a forward-looking perspective on how innovation and evidence may reshape hypertension management strategies.

Florian Rader, MD

Andrew Sharp, MD

1:30 - 2:30 p.m.

4346. ISR IVUS Image Interpretation Laptop Session

Want to use your Boston IVUS like a pro? Join one of our laptop sessions where we'll walk you through the AVVIGO+ interface, share workflow tips, and use case examples to sharpen your IVUS interpretation skills. Seats are limited and will be assigned on a first-come, first-served basis.

4 - 5 p.m.

4347. Elevating AFib Care For Veteran Patients

With a special focus on veteran patients, this program is for electrophysiologists, interventional cardiologists, referring clinicians, and AFib program leaders committed to scalable, system-level improvement even in resource-constrained environments. This compelling program guided by the Four Pillars of atrial fibrillation (AFib) management showcases how evidence-based, fully integrated AFib solutions can unlock greater access, streamline care delivery, and elevate outcomes for patients. Beginning with a candid "State of the State" on AFib care, Dr. Creighton Don will examine the burden of disease and where innovation can meaningfully elevate care delivery. Dr. Brad Sutton will bring the evidence to life, translating data insights into practical, real-world strategies that empower confident, consistent, data-driven decisions. An expert panel of VA physicians will demonstrate how scalable program design, state-of-the-art ablation and LAAC technologies, and coordinated long-term management can work together to build a seamless, end-to-end AF pathway.

Creighton W. Don, MD, MPH

Brad Sutton, MD, CMO

AF Solutions, Boston Scientific

PRIME TIME EVENTS

6 - 8 a.m.

4516. Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges For Meeting LDL-C Targets

Hilton Riverside, Grand Ballroom D

Elevated low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD), reinforcing the importance of lowering LDL-C to reduce cardiovascular risk. When statins fail to help patients reach their LDL-C targets, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors play a crucial role in guideline-recommended therapy. Approved options are available as injectable agents, and novel oral agents are in late-stage clinical trials. Still, many patients do not meet increasingly stringent lipid goals due to treatment inertia or nonadherence, increasing their risk of adverse outcomes. How can the cardiology team overcome these challenges?

This unique symposium from PeerView Live will mimic the interactive environment of a town hall meeting to create a curated educational experience, guided and informed by learner questions to address major clinical challenges in LDL-C management. By the end, learners will solidify their understanding of how to prioritize lipid-lowering in high-risk patients, gain expert insights on the latest evidence for approved and emerging PCSK9 inhibitor strategies and how to use them in clinical practice, and acquire new strategies for team-based care. Register today and help your patients start to meet their LDL-C targets consistently!

Sponsored by The Mended Hearts, Inc. for Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. disease-modifying therapy in oHCM management.

HEALTH EQUITY HUB

Expo, #701

9:45 - 10:45 a.m.

4705. Health Equity Across the Lifespan

Driven by social drivers of health, cardiovascular health risks and inequities emerge across an individual's lifespan. This session will feature a panel discussion that follows a patient as they age. The panel discussion will highlight critical health stages across the patient's life, including birth, childhood nutritional insecurity, pregnancy with elevated cardiometabolic risk, and old adulthood frailty and morbidities. Panelists will discuss cardiovascular inequities that begin before birth and intensify over time with social drivers of health functioning as physiological stressors that alter risk trajectories. Following the panel discussions, participants should be able to: 1) Describe how inequities in cardiovascular risk emerge across the lifespan, beginning in utero and extending through older adulthood; 2) Review models that improve equitable access to prevention and screening across the lifespan; and 3) Identify community strategies to improve equitable cardiovascular disease screening and prevention.

Jamez M. Fletcher, NP, AACC (Moderator)

Diane Holmes, DNP, FNP-BC, CHFN, AACC (Moderator)

Annette K. Ansong, MD, FACC

Karen Aspry, MD, MS, FACC

Onyedika J. Ilonze, MD, FACC

Jill A. Patton, RN, MSN, CRNP, AACC

Malissa J. Wood, MD, FACC

INDUSTRY-EXPERT THEATER 1

Expo, #2263

9:45 - 10:45 a.m.

4007. Cracking the Code: Uncover a Hidden Driver of Resistant Hypertension

Join us as leading experts uncover the role of hypercortisolism as a hidden driver of resistant hypertension and share their clinical insights to help identify this often-overlooked contributor.

Matthew J. Budoff MD, FACC, FAHA

Professor of Medicine

UCLA School of Medicine, Los Angeles, CA

Luke J. Laffin, MD, FACC

Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Co-Director, Center for Blood Pressure Disorders, Cleveland Clinic Cleveland, OH

Pam R. Taub, MD, FACC, FASPC

Director of Preventive Cardiology

Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center

Professor of Medicine

UC San Diego Health System, La Jolla, CA

Sponsored by Corcept Therapeutics

Noon - 1 p.m.

4008. AFib and Stroke Protection: Contemporary Management, Trials, and Practice Integration

- Translating Trial Data: LAAC Versus OAC For Stroke Protection in AF Patients
- CHAMPION AF and the Future of LAAC
- Clinical Insights into Patient Selection For LAAC

Tadeo Diaz Balderrama, MD

Christine Chung, MD

Martin Leon, MD

Sponsored by Boston Scientific

INDUSTRY-EXPERT THEATER 2

Expo, #2562

9:45 - 10:45 a.m.

4015. A Dual Focus: Managing CV Risk and Weight

This session will highlight the urgent need to address cardiovascular (CV) risk as well as to reduce weight in appropriate adult patients with overweight/obesity and established cardiovascular disease (CVD). Data from a cardiovascular outcomes trial (CVOT) will be reviewed, along with complementary real-world evidence, as well as data from relevant chronic weight-management trials. Safety data, dosing, and administration details will also be discussed.

Sanjay Rajagopalan, MD, MBA, FACC, FAHA

Chief, Cardiovascular Medicine and Chief Academic and Scientific Officer

University Hospitals Harrington Heart & Vascular Institute
Herman K. Hellerstein MD, Professor of Cardiovascular Medicine
Professor, Department of Internal Medicine and Biomedical Engineering
Case Western Reserve University
Cleveland, Ohio

Sponsored by Novo Nordisk

Noon - 1 p.m.

4016. Uncovering the Unseen: How Flycado is Changing the Game in CAD Diagnosis

Join leading experts as they share real-world insights on how Flycado transformed their care by detecting coronary artery disease that other modalities or radiotracers might miss. Through compelling case examples and clinical experience, discover how this innovation is helping clinicians identify hidden disease, improve diagnostic confidence, and ultimately improve patient outcomes.

Mouaz H. Al-Mallah, MD

Houston Methodist

Sponsored by GE Healthcare

INDUSTRY-EXPERT THEATER 3

Expo, #2863

9:45 - 10:45 a.m.

4023. Cracking the Code: Managing Hypercortisolism-Driven Resistant Hypertension in the Modern Era

Resistant hypertension remains a significant clinical challenge, affecting a substantial proportion of patients despite the availability of multiple antihypertensive therapies. Emerging evidence highlights hypercortisolism – both overt and subclinical – as an underrecognized and potentially reversible cause of resistant hypertension. However, the nonspecific presentation of hypercortisolism and the overlap with other comorbidities often delay diagnosis and effective treatment. Join us for this live educational activity that will enhance your clinical knowledge, competence, and confidence in identifying and managing hypercortisolism in the context of resistant hypertension. The panel of experts will present the latest clinical data and emerging treatments through an engaging case-based format. They will highlight new findings, including recent advances with selective cortisol receptor modulators.

Richard J. Auchus, MD, PhD, FACE

The James A. Shayman and Andrea S. Kevrick Professor of Translational Medicine
Division of Metabolism, Endocrinology and Diabetes
Departments of Internal Medicine and Pharmacology
University of Michigan Medical School
Ann Arbor, Michigan

Deepak L. Bhatt, MD, MPH, MBA

Director, Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Raymond R. Townsend, MD, FAHA

Professor Clinician Educator of Medicine
Department of Internal Medicine/Renal
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Sponsored by Corcept Therapeutics

Noon - 1 p.m.

4024. Discover the First and Only FDA- Approved Nasal Spray to Treat PSVT in Adults

Don't miss this exciting presentation by Dr. Farhad Rafii, a clinical study investigator for this clinical trial in PSVT. Join us for a discussion on potential role of this emerging therapy to treat symptomatic episodes of PSVT in adult patients.

Farhad Rafii, MD, FACC, CCDS

Interventional Cardiology Medical Group.
Assistant Clinical Professor of Medicine, Western University of Health Sciences
Adjunct Clinical Professor of Medicine, Keck School of Medicine of USC, Volunteer Faculty

Sponsored by Milestone Pharmaceuticals

ACC.26 EXPO GUIDE - MONDAY, MARCH 30

INNOVATION STAGE

Expo, #2064

10 - 10:30 a.m.

4210. Reframing Cardiovascular Risk Assessment: The Role of CCTA and Plaque Analysis

After participating in this session, attendees will be able to:

- Describe how quantitative coronary plaque assessment informs cardiovascular risk assessment
- Explain the role of CCTA and Heartflow Plaque Analysis in moving beyond traditional risk calculators for more precise risk stratification
- Discuss the intersection of advanced imaging with the new cholesterol guidelines, including implications for identifying patients who may benefit from earlier or intensified therapy

Ron Blankstein, MD

Harvard Medical School
Brigham and Women's Hospital
Boston, MA

Seth Martin, MD

Yale School of Medicine
New Haven, CT

Sponsored by Heartflow

11:45 a.m. - 12:15 p.m.

4211. Treating Hyperkalemia: A Critical Step in Heart Failure Management

This session will explore the risk of hyperkalemia (HK) among patients with heart failure and its impact on the use of RAASi or MRA therapies. The discussion will highlight guideline recommendations and clinical evidence supporting potassium binders as effective options to treat HK. Treating HK may enable the continuation of RAASi/MRA therapy. A case-based example will illustrate practical integration into patient care.

Sponsored by AstraZeneca

GE HEALTHCARE INTERACTIVE LEARNING LAB #1

Room 222

Sponsored by GE Healthcare

9 - 9:30 a.m.

4317. Cardiac PET Clarity: Applying the Latest Recommendations to Patient Selection

Gain confidence in selecting the right patients for cardiac PET by diving into the most up-to-date society guidelines and appropriate-use criteria. This interactive learning lab will review key recommendations from leading organizations, outline clinical scenarios where PET delivers unique value, and provide practical decision-making tools to help you apply evidence-based criteria in

real-world practice. Through case examples and discussion, you'll learn how to optimize patient care by aligning the right test with the right patient at the right time.

Marcelo Fernando DiCarli, MD

B&W

10 - 10:30 a.m.

4318. Uncovering Hidden Disease: Flyrcado Case Review Lab

Step inside the Flyrcado Case Review Lab and explore real-world patient cases that reveal the true power of cardiac PET. See how advanced imaging with Flyrcado™ uncovered disease that other modalities missed, and how these insights changed care decisions and improved outcomes. This interactive learning experience will highlight the clinical value of cardiac PET, demonstrate its impact on referral pathways, and give you practical takeaways for applying these insights in your practice.

Jamie Bourque, MD

UVA

GE HEALTHCARE INTERACTIVE LEARNING LAB #2

Room 225

Sponsored by GE Healthcare

9:30 - 10:30 a.m.

4362. 4D Valves: Cropping and Multiplanar Reconstruction of 4D TEE

- Learn how to manipulate 4D TEE echo images
- Review valve orientations needed for Structural Valve Procedures and surrounding anatomical landmarks on 4D TEE
- Discover the methods of Multi-Planar Reconstruction (Flexi-Slice)
- Learn how MPRs Flexi-Slice can help with procedural guidance and measurements
- Practice manipulating 4D images from real cases on EchoPac laptops

Renuka Jain, MD, FACC

Director of Echocardiography,
Aurora St. Luke's Medical Center
Milwaukee, WI

11 a.m. - Noon

4371. Artificial Intelligence in Echo: Using AI and Vivid Technologies to Improve Echo Lab Workflow

- Understand the types of artificially intelligent tools that are available in Echo
 - View Recognition
 - Measurements - Cardiac Auto Doppler, Easy AFI, Auto EF
 - Image Acquisition Guidance with Caption
 - Offline analysis and reporting with Echo Pilot on View Point
- Discover other technologies that can help make your Echo Lab more efficient
- Review images on EchoPAC and how to apply AI

Jacob Dewees, RDCS
Clinical Luminary
Leader, GE HealthCare , CVUS

BOSTON SCIENTIFIC INTERACTIVE LEARNING LAB

Room 227

Sponsored by Boston Scientific

9 a.m. - Noon

4348. LUX-Dx Hands-On Training Session

ACTIVATE YOUR **FREE** **ACC ANYWHERE** SUBSCRIPTION

Missed a Session?
Watch it On
Demand With
ACC Anywhere!

Your ACC.26 registration includes a **3-month FREE trial of ACC Anywhere**, giving you on demand access to **1,000+ videos from ACC.26**.

Log in now for a chance to WIN Bose QuietComfort Earbuds*
- perfect for watching videos on the go!

- Scan the QR Code or Visit ACC.org/ACCAnywhere
- Select Login and Enter Your ACC Username & Password
- Start Watching Videos



*ACC.26 attendees who log in from March 28-30 will automatically be entered into the drawing. The winner will be selected at random and notified by email.

3-month free trial begins March 28 regardless of the date of account activation and is available to professional attendees only.



**Visit ACC Central, Booth 1337,
to learn more!**





AMERICAN
COLLEGE of
CARDIOLOGY®

ACC IS TRANSFORMING CARDIOVASCULAR CARE FOR ALL

Visit **ACC CENTRAL, BOOTH #1337**, to discover how ACC supports you by providing:

- **Trusted education** that is **convenient, comprehensive and impactful** delivered through **ACC's SAPs** – plus maintain your certification for free with the CMP.
- **The power of a community** united – join during ACC.26 to SAVE!
- **Innovative solutions** to support the entire care team delivered through our **practice and quality improvement tools, JACC Journals** and **CardioSmart**.
- **Data-driven insights** to improve patient outcomes with the support of **NCDR Registries** and **ACC Accreditation Services**.
- **Clinical guidance at the point of care** through our partnership with **OpenEvidence** – stop by to demo the platform.

Plus, stop by to purchase apparel and accessories from the ACC Store!

EXHIBITORS - BY BOOTH NUMBER

100		327	Boston Scientific	4B	Cardiac Society of Nepal	1200	
100	Louisiana Cardiology Associates	337	Kiniksa Pharmaceuticals	5A	Israel Heart Society	1201	Mayo Clinic
101	VitalConnect	400		5B	Cardiology Society of Serbia & Cardiology Society of Srpska	1209	NewAmsterdam Pharma
102	Prisma Health	419	Esperion Therapeutics, Inc	6A	ACC Argentina Chapter	1218	CathWorks
104	American Society of Echocardiography	447	Docs Medical Billing, LLC	7A	Venezuela Society of Cardiology	1224	Shockwave Medical
106	The PERT Consortium	449	Mentice	7B	Brazil Society of Cardiology	1226	Johnson & Johnson MedTech
107	National Board of Echocardiography	453	Epic Physician Staffing	8A	Lebanese Society of Cardiology	1253	Viatriis
108	Alliance for Physician Certification and Advancement (APCA)/CBCCT, CBNC, CBCMR	455	Viking Therapeutics Inc.	8B	Mexican Society of Cardiology	1300	
109	HeartLung.AI	457	Southern Ohio Medical Center	854	Global Learning Collaborative	1301	Duke Clinical Research Institute
110	Amyloidosis Foundation	500		855	World Heart Federation	1309	Bayer US
111	Women As One	526	Medtronic	900		1319	Piedmont Healthcare
112	MicroLife USA Inc	536	Merck & Co., Inc	901	Veterans Health Administration	1325	Novartis Pharmaceuticals Corporation
113	Regeneron	546	JAYPEE BROTHERS MEDICAL PUBLISHERS PVT LTD	903	PracticeLink	1337	ACC Central
126	Baxter	547	Ultramics	907	Enara Health	1357	Metabolic Endocrine Education Foundation
140	Cardiovascular Business Magazine	548	Heartfelt Technologies Ltd	909	eClinicalWorks	1400	
142	Viscardia, Inc.	585		913	Care Access	1401	CVRx, Inc.
144	RWJBarnabas Health	600		919	Northwell Health	1409	Cardialysis
148	Future Hub	601	United Therapeutics	921	SQ Innovation, Inc.	1415	Best Vascular, Inc.
FH2	Alnylam Pharmaceuticals, Inc.	609	AdventHealth	925	TIMI Study Group, Brigham & Women's Hospital	1419	UT Southwestern
FH3	Veradigm	613	Banner Health	929	Merge	1456	Family Heart Foundation
FH8	CorVista Health	619	scPharmaceuticals	942	Inter-American Society of Cardiology	1457	PsyMed Health
FH12	Synapse Social	625	Novo Nordisk	943	European Society of Cardiology	1500	
FH13	JVPLabs	637	Abbott	1000		1514	Best Vascular, Inc.
FH14	MyOme	645	American Heart Association	1001	Eko Health	1519	LSI (Life Systems International)
FH15	Medical AI	646	Radcliffe Cardiology	1004	Arrowhead Pharmaceuticals	1556	Carle Health
FH16	UltraSight	700		1006	HCA Healthcare	1557	Daxor Corporation
FH17	Roon	708	Global Medical Staffing	1008	Springer Nature	1600	LocumTenens.com
FH19	eMyosound	710	Corstasis Therapeutics Inc	1009	BridgeBio Pharma, Inc.	1601	Edwards Lifesciences
FH20	Abcentra LLC	737	Amarin Pharma Inc	1010	Arineta	1602	OMRON Healthcare
FH21	Prevencio, Inc.	743	Elucid	1018	VectraCor, Inc.	1606	McGraw Hill
FH22	Prolocor, Inc.	749	American Heart Association	1019	Ionis Pharmaceuticals, Inc.	1608	Peerbridge Health
FH23	OpenEvidence	755	HeartLife Foundation	1020	Ionis Pharmaceuticals Disease State	1613	Pritikin ICR
200		757	MultiCare Pulse Heart Institute	1022	The Doctors Company	1637	Idorsia
206	Kaneka Medical America, LLC	800		1024	Cordis	1645	Cleerly Inc.
209	HeartBeam	818	Terumo Interventional Systems	1025	Merck & Co., Inc	1651	MedAxiom, An ACC Company
210	Adventist HealthCare, Inc.	819	BMS/J&J Alliance	1026	AskBio	1656	Cardiac CT Training with Dr. Matthew Budoff
211	Med Tech Solutions	836	iCOR Medical. LLC	1028	JenaValve Technology	1657	Wellstar Health System
212	Regeneron Pharmaceuticals Medical Affairs	837	Pfizer	1036	AstraZeneca	1700	
213	Billings Clinic Health System	843	LIB Therapeutics	1046	Sparrow BioAcoustics	1712	Tempus
215	AcuityMD	847	International Chapters	1047	The John Ritter Foundation for Aortic Health	1713	Cleveland Clinic
219	Viz.ai	1A	British Cardiovascular Society	1054	INVIVYD	1716	Sarfez Pharmaceuticals
227	Medscape from WebMD	1B	Pakistan Cardiac Society	1056	Bayhealth Medical Center	1718	Samodrei LLC
236	Alnylam Pharmaceuticals, Inc.	2A	Chinese Cardiovascular Association	1100		1726	GE HealthCare
244	PaceMate LLC	2B	Philippine Heart Association Inc	1137	Amgen	1737	Philips
245	Association of Black Cardiologists	3A	Hellenic Society of Cardiology	1146	CDC Foundation	1745	Zywie Healthcare
246	Pulnovo Medical	4A	Great Wall International Congress of Cardiology (GW-ICC)	1150	Mineralys Therapeutics	1751	Anumana, Inc.
247	Erlanger					1756	SYSTOLE
300						1757	HeartSciences
308	Sunoh.ai					1800	
312	Epic					1801	Core Sound Imaging
319	Milestone Pharmaceuticals					1803	AISAP

EXHIBITORS - BY BOOTH NUMBER

1819 Sensydia	1957 The Black Health Matters Foundation	2354 NashBio	2653 Story Health by Innovaccer
1821 AliveCor	2000	2355 Onvida Health (Yuma Regional Medical Center dba Onvida Health)	2654 Royal Surgical Associates
1825 InBody	2009 CERC	2356 CT Assist	2655 Softlink International, Inc
1827 Kardigan	2013 Murj	2357 WearLinQ	2656 Sky Labs
1831 Elsevier	2019 FUJIFILM Healthcare Americas Corporation	2400	2657 Cardio Flow Design Inc.
1837 Upbeat Cardiology Solutions	2056 Advocate Health	2437 ZOLL Medical Corporation	2700
1839 Heart Failure Society of America	2057 AstraZeneca	2443 Houston Methodist Hospital	2737 Agepha Pharma FZ-LLC
1841 Medicus Healthcare Solutions	2100	2447 CompHealth	2741 Eckert Wordell
1843 Presbyterian Healthcare Services	2108 Hayes Locums	2448 Imbria Pharmaceuticals	2745 Jubilant Radiopharma
1845 Healow Genie	2127 Bristol Myers Squibb	2450 CheckedUp	2748 SmartCardia, Inc.
1849 Intellia Therapeutics, Inc.	2137 CDL Nuclear Technologies	2452 Cardiovascular Logistics	2749 Lee Health
1853 The Villages Health	2143 BlinkRx	2453 DeLorean Artificial Intelligence	2750 Healthcasts
1855 EchoNous	2149 Amyloidosis Support Groups, Inc.	2454 Vivalink	2752 Vascentis
1856 CommonSpirit Health	2153 Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company	2456 Concept Therapeutics	2753 National Blood Clot Alliance
1857 LCMC Health	2156 Veranex	2457 All Star Healthcare Solutions	2754 Cardioset Medical LTD
1900	2157 Baptist Health	2500	2755 Brevium
1900 dms-service llc	2200	2542 Hypertrophic Cardiomyopathy Association	2756 GEMMS, Inc
1901 Zio by iRhythm	2227 NeuraSignal	2543 BioBeat	2757 Sanofi
1904 QT Medical, Inc.	2229 Wolters Kluwer	2545 HealthWell Foundation	2800
1906 JAMA Network	2237 Cytokinetics	2546 BD	2836 NextGen Healthcare
1908 CardioOne	2242 Keya Medical	2549 Weatherby Healthcare	2837 Bayer
1909 Sclmage, Inc.	2248 WVU Medicine	2552 Tryon Medical	2840 4DMedical
1910 Sectra	2249 Geisinger	2553 UV Smart Technologies B.V.	2843 Prince Sultan Cardiac Center
1912 Inspire Medical Systems Inc	2252 PracticeMatch	2554 Syncardia Systems, LLC	2844 Intelli-Heart
1918 Penumbra, Inc	2253 Atlantic Medical Group	2555 Jackson & Coker	2846 Wellysis USA Inc.
1919 Heartflow	2254 DeepQure Inc.	2556 St. Peter's Health Partners Medical Associates	2848 ReactDx
1922 Cardiac Insight	2255 The Chamberlain Group	2557 Prolaio, Inc	2852 Careverse Technology PTE. LTD.
1924 Doximity	2257 Universal Health Services (UHS)	2600	2854 Emboline, Inc.
1925 Novo Nordisk	2300	2636 Bristol Myers Squibb	2856 Northern Health Authority
1928 SubletzMD LLC Db ShareMedSpace.com	2348 Edgewise Therapeutics	2648 PS&D By Providence	2900
1936 EncaptureMD by Flexible Informatics	2349 locumstory.com	2649 Mount Sinai Medical Center	2936 Cardiovascular Associates of America (CVAUSA)
1937 Siemens Healthineers	2350 Orsini - Rare Disease Pharmacy Solutions	2651 Optum (UnitedHealthcare Services, Inc.)	2937 Boehringer Ingelheim Pharmaceuticals, Inc.
1940 Anatomage, Inc.	2351 Intermountain Health	2652 Northeast Georgia Health System	3100
1944 American Kidney Fund	2352 Athelas		3137 Concept Medical
1945 Eli Lilly & Company	2353 Foundation of the National Lipid Association		
1946 SCA Health			
1948 Lexeo Therapeutics			
1952 The Permanente Medical Group			
1954 Manning Family Children's			

TAKE A BREAK

Connect with our industry partners and your colleagues during the Expo Reception on Sunday from 2:45 - 3:45 p.m.

EXHIBITORS - BY COMPANY NAME

123

4DMedical **2840**

A

Abbott **637**
 Abcentra LLC **148-FH20**
 Acarix USA, Inc. **1811**
 ACC Argentina Chapter **847-6A**
 AcuityMD **215**
 AdventHealth **609**
 Adventist HealthCare, Inc. **210**
 Advocate Health **2056**
 Agepha Pharma FZ-LLC **2737**
 AISAP **1803**
 AliveCor **1821**
 All Star Healthcare Solutions **2457**
 Alliance for Physician Certification and Advancement (APCA)/CBCCT, CBNC, CBCMR **108**
 Alnylam Pharmaceuticals, Inc. **148-FH2, 236**

Amarin Pharma Inc **737**
 American College of Cardiology (ACC Central) **1337**
 American Heart Association **645, 749**
 American Kidney Fund **1944**
 American Society of Echocardiography **104**
 Amgen **1137**
 Amyloidosis Foundation **110**
 Amyloidosis Support Groups, Inc. **2149**
 Anatomage, Inc. **1940**
 Anumana, Inc. **1751**
 Arineta **1010**
 Arrowhead Pharmaceuticals **1001**
 AskBio **1026**
 Association of Black Cardiologists **245**
 AstraZeneca **1036, 2057**
 Athelas **2352**
 Atlantic Medical Group **2253**


B

Banner Health **613**
 Baptist Health **2157**
 Baxter **126**
 Bayer **2837**
 Bayer US **1309**
 Bayhealth Medical Center **1056**
 BD **2546**
 Best Vascular, Inc. **1415, 1514**
 Billings Clinic Health System **213**
 BioBeat **2543**
 BlinkRx **2143**
 BMS/J&J Alliance **819**
 Boehringer Ingelheim Pharmaceuticals, Inc. **2937**
 Boston Scientific **327**
 Brazil Society of Cardiology **7B**
 Brevium **2755**
 BridgeBio Pharma, Inc. **1009**
 Bristol Myers Squibb **2127, 2636**

British Cardiovascular Society **847-1A**

C

Cardiac CT Training with Dr. Matthew Budoff **1656**
 Cardiac Insight **1922**
 Cardiac Society of Nepal **847-4B**
 Cardialysis **1409**
 Cardio Flow Design Inc. **2657**
 Cardiology Society of Serbia & Cardiology Society of Srpska **847-5B**
 CardioOne **1908**
 Cardioset Medical LTD **2754**
 Cardiovascular Associates of America (CVAUSA) **2936**
 Cardiovascular Business Magazine **140**
 Cardiovascular Logistics **2452**
 Care Access **913**
 Careverse Technology PTE. LTD. **2852**



EXHIBITORS - BY COMPANY NAME

Carle Health **1556**
 CathWorks **1218**
 CDC Foundation **1146**
 CDL Nuclear Technologies **2137**
 CERC **2009**
 CheckedUp **2450**
 Chinese Cardiovascular Association **847-2A**
 Cleerly Inc. **1645**
 Cleveland Clinic **1713**
 CommonSpirit Health **1856**
 CompHealth **2447**
 Concept Medical **3137**
 Concept Therapeutics **2456**
 Cordis **1024**
 Core Sound Imaging **1801**

Corstasis Therapeutics Inc **710**
 CorVista Health **148-FH8**
 CT Assist **2356**
 CVRx, Inc. **1401**
 Cytokinetics **2237**

D

Daxor Corporation **1557**
 DeepQure Inc. **2254**
 DeLorean Artificial Intelligence **2453**
 dms-service llc **1900**
 Docs Medical Billing, LLC **447**
 Doximity **1924**
 Duke Clinical Research Institute **1301**

E

EchoNous **1855**
 Eckert Wordell **2741**
 eClinicalWorks **909**
 Edgewise Therapeutics **2348**
 Edwards Lifesciences **1601**
 Eko Health **1000**
 Eli Lilly & Company **1945**
 Elsevier **1831**
 Elucid **743**
 Emboline, Inc. **2854**
 eMyosound **148-FH19**
 Enara Health **907**
 EncaptureMD by Flexible Informatics **1936**

Epic **312**
 Epic Physician Staffing **453**
 Erlanger **247**
 Esperion Therapeutics, Inc **419**
 European Society of Cardiology **943**

F

Family Heart Foundation **1456**
 Foundation of the National Lipid Association **2353**
 FUJIFILM Healthcare Americas Corporation **2019**



EXHIBITORS - BY COMPANY NAME

G		L		Orsini - Rare Disease Pharmacy Solutions	2350	ShareMedSpace.com	1928
GE HealthCare	1726	LCMC Health	1857	P		Sunoh.ai	308
Geisinger	2249	Lebanese Society of Cardiology	847-8A	PaceMate LLC	244	Synapse Social	148-FH12
GEMMS, Inc	2756	Lee Health	2749	Pakistan Cardiac Society	847-1B	Syncardia Systems, LLC	2554
Global Learning Collaborative	854	Lexeo Therapeutics	1948	Peerbridge Health	1608	SYSTOLE	1756
Global Medical Staffing	708	LIB Therapeutics	843	Penumbra, Inc	1918	T	
Great Wall International Congress of Cardiology (GW-ICC)	847-4A	locumstory.com	2349	Pfizer	837	Tempus	1712
H		LocumTenens.com	1600	Philippine Heart Association Inc	847-2B	Terumo Interventional Systems	818
Hayes Locums	2108	Louisiana Cardiology Associates	100	Philips	1737	The Black Health Matters Foundation	1957
HCA Healthcare	1006	LSI (Life Systems International)	1519	Pie Medical Imaging / Esaote	1809	The Chamberlain Group	2255
Healow Genie	1845	M		Piedmont Healthcare	1319	The Doctors Company	1022
Healthcasts	2750	Manning Family Children's	1954	PracticeLink	903	The John Ritter Foundation for Aortic Health	1047
HealthWell Foundation	2545	Mayo Clinic	1201	PracticeMatch	2252	The Permanente Medical Group	1952
Heart Failure Society of America	1839	McGraw Hill	1606	Presbyterian Healthcare Services	1843	The PERT Consortium	106
HeartBeam	209	Med Tech Solutions	211	Prevencio, Inc.	148-FH21	The Villages Health	1853
Heartfelt Technologies Ltd	548	MedAxiom, An ACC Company	1651	Prince Sultan Cardiac Center	2843	TIMI Study Group, Brigham & Women's Hospital	925
Heartflow	1919	Medical AI	148-FH15	Prisma Health	102	Tryon Medical	2552
HeartLife Foundation	755	Medicus Healthcare Solutions	1841	Pritikin ICR	1613	U	
HeartLung.AI	109	Medscape from WebMD	227	Prolaio, Inc	2557	UltraSight	148-FH16
HeartSciences	1757	Medtronic	526	Prolocor, Inc.	148-FH22	Ultromics	547
Hellenic Society of Cardiology	847-3A	Mentice	449	PS&D By Providence	2648	United Therapeutics	601
Houston Methodist Hospital	2443	Merck & Co., Inc	536, 1025	PsyMed Health	1457	Universal Health Services (UHS)	2257
Hypertrophic Cardiomyopathy Association	2542	Merge	929	Pulnovo Medical	246	Upbeat Cardiology Solutions	1837
I		Metabolic Endocrine Education Foundation	1357	Q		UT Southwestern	1419
iCOR Medical. LLC	836	Mexican Society of Cardiology	847-8B	QT Medical, Inc.	1904	UV Smart Technologies B.V.	2553
Idorsia	1637	Microlife USA Inc	112	R		V	
Imbria Pharmaceuticals	2448	Milestone Pharmaceuticals	319	Radcliffe Cardiology	646	Vascentis	2752
InBody	1825	Mineralys Therapeutics	1150	ReactDx	2848	VectraCor, Inc.	1018
Inspire Medical Systems Inc	1912	Mount Sinai Medical Center	2649	Regeneron	113	Venezuela Society of Cardiology	847-7A
Intellia Therapeutics, Inc.	1849	MultiCare Pulse Heart Institute	757	Regeneron Pharmaceuticals Medical Affairs	212	Veradigm	148-FH3
Intelli-Heart	2844	Murj	2013	Roon	148-FH17	Veranex	2156
Inter-American Society of Cardiology	942	MyOme	148-FH14	Royal Surgical Associates	2654	Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company	2153
Intermountain Health	2351	N		RWJBarnabas Health	144	Veterans Health Administration	901
INVIVYD	1054	NashBio	2354	S		Viatrix	1253
Ionis Pharmaceuticals Disease State	1020	National Blood Clot Alliance	2753	Samodrei LLC	1718	Viking Therapeutics Inc.	455
Ionis Pharmaceuticals, Inc.	1019	National Board of Echocardiography	107	Sanofi	2757	Viscardia, Inc.	142
Israel Heart Society	847-5A	NeuraSignal	2227	Sarfez Pharmaceuticals	1716	VitalConnect	101
J		NewAmsterdam Pharma	1209	SCA Health	1946	Vivalink	2454
Jackson & Coker	2555	NextGen Healthcare	2836	Sclmage, Inc.	1909	Viz.ai	219
JAMA Network	1906	Northeast Georgia Health System	2652	scPharmaceuticals	619	W	
JAYPEE BROTHERS MEDICAL PUBLISHERS PVT LTD	546	Northern Health Authority	2856	Sectra	1910	WearLinq	2357
JenaValve Technology	1028	Northwell Health	919	Sensydia	1819	Weatherby Healthcare	2549
Johnson & Johnson MedTech	1226	Norton Medical Group	1807	Shockwave Medical	1224	Wellstar Health System	1657
Jubilant Radiopharma	2745	Novartis Pharmaceuticals Corporation	1325	Siemens Healthineers	1937	Wellysis USA Inc.	2846
JVPLabs	148-FH13	Novo Nordisk	625, 1925	Sky Labs	2656	Wolters Kluwer	2229
K		O		SmartCardia, Inc.	2748	Women As One	111
Kaneka Medical America, LLC	206	OMRON Healthcare	1602	Softlink International, Inc	2655	World Heart Federation	855
Kardigan	1827	Onvida Health (Yuma Regional Medical Center dba Onvida Health)	2355	Southern Ohio Medical Center	457	WVU Medicine	2248
Keya Medical	2242	OpenEvidence	148-FH23	Sparrow BioAcoustics	1046	XYZ	
Kiniksa Pharmaceuticals	337	Optum (UnitedHealthcare Services, Inc.)	2651	Springer Nature	1008	Zio by iRhythm	1901
				SQ Innovation, Inc.	921	ZOLL Medical Corporation	2437
				St. Luke's University Health Network	1004	Zywie Healthcare	1745
				St. Peter's Health Partners Medical Associates	2556		
				Story Health by Innovaccer	2653		
				SubletzMD LLC DBa			

The Doctors Company is proud to support the

AMERICAN COLLEGE OF CARDIOLOGY



Serving those who provide care is in our DNA

ACC.26 • March 28–30, 2026 • New Orleans

Visit us at booth #1022 and discover why more cardiologists choose The Doctors Company than any other insurer.



SCAN for a rapid premium indication, and discover the unrivaled rewards of The Doctors Company.

Exclusively endorsed by



AMERICAN COLLEGE of CARDIOLOGY®



The Doctors Company
TDCGROUP